US20230039835A1 - Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof - Google Patents
Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof Download PDFInfo
- Publication number
- US20230039835A1 US20230039835A1 US17/876,791 US202217876791A US2023039835A1 US 20230039835 A1 US20230039835 A1 US 20230039835A1 US 202217876791 A US202217876791 A US 202217876791A US 2023039835 A1 US2023039835 A1 US 2023039835A1
- Authority
- US
- United States
- Prior art keywords
- patient
- cancer
- cells
- dim
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 55
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 50
- 201000011510 cancer Diseases 0.000 title claims abstract description 46
- 210000001616 monocyte Anatomy 0.000 title claims abstract description 41
- 210000000130 stem cell Anatomy 0.000 title description 42
- 238000002360 preparation method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 80
- 210000004027 cell Anatomy 0.000 claims description 148
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 59
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 58
- 210000004369 blood Anatomy 0.000 claims description 55
- 239000008280 blood Substances 0.000 claims description 55
- 239000000523 sample Substances 0.000 claims description 45
- 238000002512 chemotherapy Methods 0.000 claims description 36
- 102000003812 Interleukin-15 Human genes 0.000 claims description 31
- 108090000172 Interleukin-15 Proteins 0.000 claims description 31
- 102100030704 Interleukin-21 Human genes 0.000 claims description 29
- 108010074108 interleukin-21 Proteins 0.000 claims description 29
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 22
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 22
- 239000012472 biological sample Substances 0.000 claims description 19
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 17
- 238000003745 diagnosis Methods 0.000 claims description 17
- 239000002955 immunomodulating agent Substances 0.000 claims description 16
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 7
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 9
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 description 47
- 210000000822 natural killer cell Anatomy 0.000 description 43
- 239000003795 chemical substances by application Substances 0.000 description 29
- 238000002617 apheresis Methods 0.000 description 24
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 17
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 10
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 9
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 9
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 9
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 9
- 241000272168 Laridae Species 0.000 description 9
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 7
- 229960002169 plerixafor Drugs 0.000 description 7
- 229960004641 rituximab Drugs 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 229960004528 vincristine Drugs 0.000 description 7
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 7
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 108700014844 flt3 ligand Proteins 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 229960004618 prednisone Drugs 0.000 description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 238000000491 multivariate analysis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 230000000779 depleting effect Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 210000004395 cytoplasmic granule Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- -1 300 mg/m2) on day −6 Chemical compound 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- This document relates to materials and methods for assessing the lymphocyte to monocyte ratio (LMR) in cancer patients, and for treating cancer patients an immunostimulatory agent when the LMR is at least 1.0.
- LMR lymphocyte to monocyte ratio
- Autologous peripheral blood hematopoeitic stern cell transplantation can improve survival in various types of cancer, including myelomas and leukemias [e.g., acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)], as well as Hodgkin and non-Hodgkin's lymphomas [e.g., diffuse large B-cell lymphoma (DLBCL)], whether the APBHSCT is carried out before, after, or without chemotherapy.
- myelomas and leukemias e.g., acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
- NHL acute lymphoblastic leukemia
- AML acute myeloid leukemia
- Hodgkin and non-Hodgkin's lymphomas e.g., diffuse large B-cell lymphoma (DLBCL)
- lymphocyte to monocyte ratio in infused autologous stem cell transplants can be used as an indicator of prognosis, and also as the impetus for treating a transplant recipient with an immunostimulatory agent [e.g., interleukin-15 (IL-15) or interleukin-21 (IL-21), or a combination thereof].
- an immunostimulatory agent e.g., interleukin-15 (IL-15) or interleukin-21 (IL-21), or a combination thereof.
- a LMR that is less than 1.0 can be used as an indicator that a patient has a worse prognosis than a patient with a LMR of 1.0 or greater (e.g., such that the patient with a LMR less than 1.0 has a lower chance of progression-free survival or overall survival than a patient with a LMR of at least 1.0).
- the LMR also can be used as an indicator that a patient should be treated with an immunotherapeutic that can increase the absolute lymphocyte count (ALC) in the patient, reduce the absolute monocyte count (AMC) in the patient, or both.
- ALC absolute lymphocyte count
- AMC absolute monocyte count
- this document is based, at least in part, on the discovery that the autograft absolute monocyte count (A-AMC) in infused autologous stem cell transplants (A-AMC), as well as the AMC recovery post-APBHSCT, can be used as an indicator of prognosis.
- A-AMC autograft absolute monocyte count
- a patient receiving APBHSCT having an A-AMC that is more than 0.5 ⁇ 10 9 cells/kg may have a worse prognosis than a patient receiving APBHSCT having an A-AMC of 0.5 ⁇ 10 9 cells/kg or less.
- an A-AMC greater than 0.5 ⁇ 10 9 cells/kg can indicate that the stem cell preparation should be treated to deplete immunosuppressive monocytes before being administered to the patient.
- a population of collected autologous cells can be passed through a CD14 microbead column (Mitenyi Biotec; Bergisch Gladbach, Germany) to reduce the number of monocytes in the population before the cells are returned to the patient.
- this document is based, at least in part, on the discovery that the ratio of natural killer (NK) cells to CD14+HLA-DR DIM myeloid-derived monocytic cells in a population of autologous stem cells to be infused (A-NK:A-CD14+HLA-DR DIM ), as well as the CD14+HLA-DR DIM cell count in a population of autologous stern cells to be infused, can be used as indicators of prognosis.
- NK natural killer
- a patient receiving APBHSCT with an A-NK:A-CD14+HLA-DR DIM less than 0.29, or a CD14+HLA-DR DIM count greater than or equal to 0.21 ⁇ 10 9 cells/kg may have a worse prognosis than a patient receiving APBHSCT with an A-NK:A-CD14+HLA-De DIM of 0.29 or greater, or a CD14+HLA-DR DTM count less than 0.21 ⁇ 10 9 cells/kg (e.g., such that the patient receiving the transplant with an A-NK:A-CD14+HLA-DR DIM less than 0.29 has a lower chance of progression-free survival or overall survival than a patient receiving APBHSCT with an A-NK:A-CD14+HLA-DR DIM of at least 0.29).
- an A-NK:A-CD14+HLA-DR DIM of 0.29 or less can be an indicator that the stern cell preparation should be treated to deplete monocytes or increase NK numbers prior to transfer
- Using the methods and materials provided herein can allow clinicians to identify patients who may benefit from treatment with an immunotherapeutic such as IL-15, IL-21, and/or a monocyte depleting agent.
- an immunotherapeutic such as IL-15, IL-21, and/or a monocyte depleting agent.
- a patient Once identified as having a ratio of lymphocytes to monocytes, a CD14+HLA-DR DIM count, or a ratio of NK cells to CD14+HLA-DR DIM cells, that suggests a poor prognosis, a patient can be administered an agent (e.g., IL-15, IL-21, and/or a monocyte depleting agent) to and improve the patient's prognosis.
- an agent e.g., IL-15, IL-21, and/or a monocyte depleting agent
- this document features a method for treating a cancer patient, where the method includes (a) identifying the patient as having a biological sample with a LMR less than 1.0; and (b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent.
- the immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21.
- the LMR can have been determined at initial diagnosis of the cancer.
- the patient can be a subject who was or is to be treated with APBHSCT, and the LMR can have been determined using A-ALC and A-AMC in the APBHSCT sample prior to transfer.
- the patient can be a subject who has received an APBHSCT, and the LMR can have been calculated using ALC and AMC in a blood sample obtained from the patient after the APBHSCT (e.g., 15 days after the APBHSCT).
- the patient can be a subject treated with chemotherapy, and the LMR can have been calculated using ALC and AMC within a blood sample obtained from the patient after the chemotherapy (e.g., 15 days after the chemotherapy).
- the chemotherapy can include treatment with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP), and a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
- cyclophosphamide doxorubicin, vincristine, prednisone
- rituximab a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
- RCHOP a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- The can include identifying the patient as having a LMR less than 0.9, and administering a pharmaceutical composition comprising IL-15, IL-21, or a combination of IL-15 and IL-21.
- the method can include administering IL-15 and IL-21 simultaneously, or administering IL-15 and IL. 21 separately.
- the method can further include conducting a positron emission tomography (PET) scan on the patient.
- PET positron emission tomography
- this document features a method for treating a cancer patient, where the method includes (a) identifying the patient as having a biological sample with a natural killer (NK):CD14+HLA-DR D ′′ ratio less than 0.29; and (b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent.
- the immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21.
- the NK:CD14+HLA-DR DIM ratio can have been determined at initial diagnosis of the cancer.
- the patient can be a subject who was or is to be treated with APBHSCT, and the NK:CD14+HLA-DR DTM ratio can have been determined using absolute NK cell count and absolute CD14+HLA-DR DIM count in the APBHSCT sample prior to transfer.
- the patient can be a subject who has received an APBHSCT, and the NK:CD14+HLA-DR DIM ratio can have been calculated using absolute NK cell count and absolute CD14+HLA-DR DIM count in a blood sample obtained from the patient after the APBHSCT (e.g., 15 days after the APBHSCT).
- the patient can be a subject who was treated with chemotherapy, and the NK cell count can have been calculated using absolute NK cell count and absolute NK:CD14+HLA-DR DIM count within a blood sample obtained from the patient after the chemotherapy (e.g., 15 days after the chemotherapy).
- the chemotherapy can include treatment with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD.
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- the method can include identifying the patient as having a NK:CD14+HLA-DR DIM ratio less than 0.25, and administering a pharmaceutical composition comprising IL-15, IL-21, or a combination of IL-15 and IL-21.
- the method can include administering IL-15 and IL-21 simultaneously or separately.
- the method can further include conducting a PET scan on the patient.
- this document features a method for identifying a cancer patient as having an increased likelihood of survival, where the method includes (a) determining that a biological sample containing cells from the patient has a LMR of at least 1.0 or a NK:CD14 ⁇ HLA-DR DIM of at least 0.29; and (b) classifying the patient as having an increased likelihood of survival, as compared to a patient having a LMR less than 1.0 or a NK;CD14+HLA-DR DIM less than 0.29.
- the biological sample can contain autologous stem cells collected via an apheresis procedure.
- the biological sample can be a blood sample obtained from the patient before or after treatment with chemotherapy or APBHSCT.
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- the patient can be a subject who has been treated with chemotherapy or APBHSCT, and the survival can be progression-free survival.
- this document features a method for identifying a cancer patient as having a decreased likelihood of survival, where the method includes (a) determining that a biological sample containing cells from the patient has a LMR less than 1.0 or a NK:CD14 ⁇ HLADR DIM less than 0.29; and (b) classifying the patient as having a decreased likelihood of survival, as compared to a patient having a LMR of at least 1.0 or a NK:CD14+HLA-DR DIM of at least 0.29.
- the biological sample can contain autologous stem cells collected via an apheresis procedure.
- the biological sample can be a blood sample obtained from the patient before or after treatment with chemotherapy or APBHSCT.
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer esophageal cancer, gastric cancer, and pancreatic cancer.
- the patient can be a subject who has been treated with chemotherapy or APBHSCT, and the survival can be progression-free survival.
- This document also features a method for treating a population of autologous cells collected from a cancer patient, where the method includes (a) determining that the population of cells has a LMR less than 1.0 or a NK:CD14+HLA-DR DIM less than 0.29; and (b) contacting the population of cells with an agent that depletes monocytes.
- the agent can include a support coupled to CD14.
- this document features a method for treating a cancer patient, where the method includes (a) identifying the patient as having a biological sample as containing an A-CD14′HLA-DR DIM cell count that is greater than or equal to 0.21 ⁇ 10 9 cells/kg; and (b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent.
- the immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21.
- the number of A-CD1441LA-DR DIM cells can have been determined at initial diagnosis of the cancer.
- the patient can be a subject who was or is to be treated by APBHSCT, where the A-CD14 +HLA-DR DIM count was determined using absolute CD14+HLA-DR DIM count in the APBHSCT sample prior to transfer.
- the patient can have received an APBHSCT, where the A-CD 14 + HLA-DR DIM count was calculated using absolute CD14+HLA-DR DIM count in a blood sample obtained from the patient after the APBHSCT.
- the blood sample can have been obtained 15 days after the APBHSCT.
- the patient can be a subject who was treated with chemotherapy, where the LM A-CD14′HLA-DR DIM count was calculated using absolute A-CD14 + HLA-DR DIM count within a blood sample obtained from the patient after the chemotherapy (e.g., 15 days after the chemotherapy).
- the chemotherapy can have included one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD.
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- the method can further include conducting a PET scan on the patient.
- this document features the use of a pharmaceutical composition containing an immunotherapeutic agent for treating a cancer patient, where the cancer patient is identified as having a biological sample with a LMR less than 1.0.
- the immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21.
- the LMR can have been determined at initial diagnosis of the cancer.
- the patient can be a subject who was or is to be treated by APBHSCT, where the LMR was determined using absolute lymphocyte count and absolute monocyte count in the APBHSCT sample prior to transfer.
- the patient can be a subject who has received an APBHSCT, where the LMR was calculated using absolute lymphocyte count and absolute monocyte count in a blood sample obtained from the patient after (e.g., 15 days after) the APBHSCT.
- the patient can be a subject who was treated with chemotherapy, where the LMR was calculated using absolute lymphocyte count and absolute monocyte count within a blood sample obtained from the patient after (e.g., 15 days after) the chemotherapy.
- the chemotherapy can include treating with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD.
- the cancer can be is selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- the patient can be identified as having a LMR less than 0.8.
- this document features the use of a pharmaceutical composition containing an immunotherapeutic agent for treating a cancer patient identified as having a biological sample with a NK:CD14+HLA-DR D ′′ ratio less than 0.29.
- the immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21.
- the NK:CD14+HLA-DR DIM ratio can have been determined at initial diagnosis of the cancer.
- the patient can be a subject who was or is to be treated by APBHSCT, where the NK:CD14+HLA-DR DIM ratio was determined using absolute NK cell count and absolute CD14+HLA-DR DTM count in the APBHSCT sample prior to transfer.
- the patient can be a subject who has received an APBHSCT, where the NK:CD14+HLA-DR DIM ratio was calculated using absolute NK cell count and absolute CD14+HLA-DR DIM count in a blood sample obtained from the patient after (e.g., 15 days after) the APBHSCT.
- the patient can be a subject who was treated with chemotherapy, where the NK:CD14+HLA-DR DIM ratio was calculated using absolute NK cell count and absolute CD14-FHLA-DR DIM count within a blood sample obtained from the patient after (e.g., 15 days after) the chemotherapy.
- the chemotherapy can include treating with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD.
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- the cancer patient can be identified as having a NK:CD14+HLA-DR DIM ratio less than 0.25.
- this document features the use of a pharmaceutical composition containing an immunotherapeutic agent for treating a cancer patient identified as having a biological sample as containing an A-CD14 ⁇ ′HLA-DR DIM cell count greater than or equal to 0.21 ⁇ 10 9 cells/kg.
- the immunotherapeutic agent can be IL-15, 1L-21, or a combination of IL-15 and IL-21.
- the number of A-CD14 ⁇ ′HLA-DR Dim cells can have been determined at initial diagnosis of the cancer.
- the patient can be a subject who was or is to be treated by APBHSCT, where the A-CD1411LA-DR DIM count was determined using absolute CD14+HLA-DR DIM count in the APBHSCT sample prior to transfer.
- the patient can be a subject who received an APBHSCT, where the A-CD 14 + HLA-DR DIM count was calculated using absolute CD14+HLA-DR DIM count in a blood sample obtained from the patient after (e.g., 15 days after) the APBHSCT.
- the patient can be a subject who was treated with chemotherapy, where the LM A-CD1441LA-DR DIM count was calculated using absolute A-CD14′11LA-DR DIM count within a blood sample obtained from the patient after (e.g., 15 days after) the chemotherapy.
- the chemotherapy can include treating with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD.
- the cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or selected from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- FIGS. 1 A and 1 B are a series of Kaplan-Meier plots showing overall survival (top), progression-free survival (middle), and lymphoma-specific survival (bottom) for DLBCL patients treated with APBHSCT, using a population of autologous cells having an A-LMR of 1 or greater, or less than 1, as indicated.
- FIGS. 2 A- 2 E are a series of fluorescence-activated cell sorting (FACS) scatter plots.
- FIG. 2 A autograft lymphocytes were gated on a forward scatter (FSC)/side scatter (SSC) plot.
- FIG. 2 B autograft natural killer cells (CD16 + , CD56 + , CD3 ⁇ ) were enumerated from the lymphocyte-positive gate.
- FIG. 2 C autograft monocytes were gated on a FSC/SSC plot.
- FIG. 2 D autograft monocytes were further gated to determine CD14 + cells.
- FIG. 2 E autograft CD14 ⁇ HLA-De lm were enumerated from the CD14′ gate.
- FIGS. 3 A and 3 B are graphs plotting the Receiver Operating Characteristic (ROC) and area under the curve (AUC) for A-NK:A-CD14 ⁇ HLA-DR DIM ratio.
- FIGS. 4 A- 4 D are a series of Kaplan-Meier plots showing, OS or PFS for non-Hodgkin lymphoma patients treated with APBHSCT using various populations of autologous cells.
- FIG. 4 A OS for A-CD14 + HLA-DR DIM ⁇ 0.21 ⁇ 10 9 cells/kg vs.
- A-CD14′HLA-DR DIM >0.21 ⁇ 10 9 cells/kg.
- FIG. 4 B PFS for A-CD14 ⁇ HLA-DR D1m ⁇ 0.21 ⁇ 10 9 cells/kg vs.
- A-CD141-ILA-DR DIM >0.21 ⁇ 10 9 cells/kg.
- FIG. 4 C OS for A-NK:A-CD14 + FILA-DR DIM ratio >0.29 vs.
- A-NK:A-CD141-ILA-DR DIM ratio ⁇ 0.29.
- FIG. 4 D PFS for A-NK:A-CD14′11LA-DR DIM ratio >0.29 vs.
- A-NK:A-CD141-ILA-DR DIM ratio ⁇ 0.29.
- This document provides materials and methods that for treating cancer patients, and is based, at least in part, on the discoveries that A-LMR and LMR, as well as A-AMC, AMC, and A-NK:A-CD14+HLA-DR DIM , can be powerful indicators of cancer patient prognosis.
- this document provides materials and methods for obtaining a population of stem cells and/or treating a patient to achieve an A-LMR or a LMR of at least 1.0, as well as materials and methods for obtaining a population of stern cells and/or treating a patient to achieve an A-NK:A-CD14+HLA-DR DIM or NK:CD14+HLA-DR DIM of at least 0.29.
- a subject treated according to the methods described herein can be a human cancer patient diagnosed with, for example, non-Hodgkin lymphoma, Hodgkin's disease, classical Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, or acute lymphoblastic leukemia, or a solid tumor such as a breast tumor, lung tumor, ovarian tumor, liver tumor, or kidney tumor.
- the methods provided herein can include the step of returning a population of collected autologous cells to the patient.
- the cell population can be returned to the patient by, for example, intravenous infusion or any other suitable method known in the art.
- the patient can be in remission from the cancer, either prior to collection of the cells or prior to returning the cells to the patient.
- autologous refers to a graft in which the donor and recipient is the same individual.
- allogeneic transplant refers to a graft in which the donor and recipient are genetically non-identical individuals from the same species.
- xenogeneic transplant refers to a graft in which the donor and recipient are of different species.
- an APBHSCT refers to a procedure in which a sample of a subject's own stem cells are removed and subsequently transplanted back into the same subject.
- Stem cells can be harvested from bone marrow (BM) or peripheral blood (PB), for example. Once obtained, stem cells can be frozen until needed.
- stem cells can be obtained from a patient, cryopreserved at temperatures ⁇ 85° C., and then thawed and returned (i.e., transplanted, typically by transfusion) to the patient.
- stem cell aliquots can be thawed, loaded into one or more sterile syringes or infusion bags, and injected intravenously over a period of time ranging from about 30 minutes to about 45 minutes.
- stem cells capable of reconstituting a patient's immune system can be obtained from the patient's peripheral circulation following mobilization of such cells from BM into PB.
- Mobilization of stem cells can be accomplished by treatment of a patient with one or more factors that can (i) stimulate an increase in proliferation of stem cells and/or progenitor cells, and/or (ii) stimulate migration of stem cells and/or progenitor cells from the BM into the peripheral circulation.
- factors can be administered with adjuvants and/or other accessory substances, separately or in combination as desired.
- factors examples include, without limitation, granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), c-kit ligand (stem cell factor (SCF)), interleukin-2, -7, -8, and -12 (IL-2, IL-7, IL-8, and IL-12), and flt-3 ligand.
- G-CSF granulocyte colony-stimulating factor
- GM-CSF granulocyte/macrophage colony-stimulating factor
- SCF stem cell factor
- interleukin-2, -7, -8, and -12 interleukin-2, -7, IL-8, and IL-12
- flt-3 ligand interleukin-2, -7, -8, and IL-12
- Factors to be administered can include, for example, G-CSF alone (e.g., 10 ug/kg/day G-CSF), G-CSF+flt-3 ligand (e.g., 10 ug/kg/day G-CSF+50 mg/kg/day flt-3 ligand), or GM-CSF+flt-3 ligand (e.g., 5 ⁇ g/kg/day GM-CSF+50 ug/kg/day flt-3 ligand). See, e.g., Sudo et al. (1997) Blood 89:3186.
- Such factors can be administered prior to harvest or starting on the day of harvest, for example, and can be given on a daily basis for one to seven days (e.g., for one, two, three, four, five, six, or seven days), or until stern cell harvesting is complete.
- Factors that stimulate stern cell proliferation or mobilization can be administered using any suitable method. Typically, such factors can be administered parenterally (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip).
- Mobilization of stem cells with, for example, GM-CSF and flt-3 ligand can be evaluated by determining the number of CD34 + cells present before, during, and/or after treatment with one or more mobilizing agents. In some embodiments, the number of CD34 + cells can be determined by FACS analysis using CD34-specific antibodies conjugated to fluorescent or other labeling moieties.
- peripheral blood stem cells can be collected using, for example, an apheresis procedure.
- apheresis which is well known in the art, involves removal of whole blood from a patient or donor. Within an instrument that is essentially designed as a centrifuge, the components of the whole blood are separated. One or more of the separated portions is then withdrawn, and the remaining components can be retransfused into the patient or donor.
- all or most (e.g., 80%, 90%, 95%, 99%, or 100%) of the erythrocytes in a sample of whole blood can be returned to a patient during an apheresis procedure, while lymphocytes (e.g., NK cells) and stem cells can be collected.
- lymphocytes e.g., NK cells
- Apheresis can be performed as many as four times per week (e.g., one, two, three, or four times per week).
- a commercially available blood cell collection device can be used, such as the CS3000® blood cell collection device or the Fenwal Amicus collection device, both of which are marketed by the Fenwal Division of Baxter Healthcare Corporation (Fenwal Laboratories, Deerfield, Ill.).
- a total blood volume between 9.5 and 10 L per apheresis procedure can be processed at a flow rate of 50 to 90 mL/min.
- a cell count can be performed on an aliquot of the total product to determine the number of stein cells.
- Cells can be collected until the total sample taken from the patient reaches a concentration of at least 2 ⁇ 10 6 CD34′ stein cells/kg (e.g., 2 ⁇ 10′ CD34′ cell/kg to 3 ⁇ 10′ CD34′ cells/kg, 2 ⁇ 10 6 CD34′; cells/kg to 2.5 ⁇ 10 6 CD34 ⁇ ′ cells/kg, or 2.5 ⁇ 10 6 CD34′ cell/kg to 3 ⁇ 10 6 CD34′ cells/kg).
- PBSC mobilization may not collect from some patients during a single apheresis procedure. In these patients, BM harvest or a second attempt at PBSC mobilization can be performed. Alternatively, these patients may be excluded from proceeding to APBHSCT.
- Apheresis products can be centrifuged (e.g., at 400 g for 10 minutes), and the plasma can be removed to yield a total volume of, for example, about 100 mL.
- the resulting cell suspension can be mixed with a physiological freezing solution [e.g., 100 mL minimal essential medium such as MEM-S(Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 20% dimethylsulfoxide (DMSO)].
- Cell/media suspensions can be transferred to freezing bags (such as those manufactured by Delmed, Canton, Mass.) or any other freezing receptacle known in the art, and frozen to ⁇ 100° C. using, for example, a computer-controlled cryopreservation device (e.g., the Cryoson-BV-6; Cryoson Deutschland GmbH, FRG).
- the cells then can be transferred into liquid nitrogen and stored at until transplantation.
- Patients typically undergo a pre-transplant workup to evaluate, for example, heart, liver, kidney, and lung function, as well as current disease status.
- patients deemed to be eligible (e.g., healthy enough) for APBHSCT are subjected to a tumor debulking procedure prior to APBHSCT.
- a patient can be treated with high doses of chemotherapy, radiation therapy, and/or surgery (e.g., surgery with anesthesia) before the transplant.
- Stern cells for transplant typically are collected prior to tumor debulking regimens, since such potentially lethal procedures can be immunosuppressive and can severely damage or destroy the BM.
- APBHSCT following a debulking procedure can reconstitute the patient's immune cells with stem cells present in the transplant.
- a patient's stem cells can be collected by BM harvest using procedures known in the art, or by a stem cell apheresis procedure as described above, for example. Collected stem cells can be cryopreserved, and the patient can undergo a debulking procedure such as high-dose chemotherapy and/or radiation therapy. After the debulking procedure is completed, the patient's stem cells can be transplanted.
- APBHSCT can be done almost immediately after a debulking procedure (e.g., 24 to 48 hours after HDT). Alternatively, a longer period of time (e.g., a week to several months) can elapse between a debulking procedure and APBHSCT.
- Endograftment refers to a process whereby the transplanted stem cells begin to differentiate into mature blood cells.
- stem cells can be treated prior to transplantation with, for example, anticancer drugs or antibodies to reduce the number of cancerous cells that may be present in the sample. Such procedures are referred to as “purging.”
- subjects e.g., cancer patients
- Lymphocytes are white blood cells (WBC) that are formed in lymphatic tissue throughout the human body (e.g., lymph nodes, spleen, thymus, tonsils, Peyer's Patches, and bone marrow). In normal adults, lymphocytes comprise approximately 22% to 28% of the total number of leukocytes in the circulating blood.
- lymphocyte includes NK cells, B cells, and T cells (e.g., T helper cells, cytotoxic T cells, and T suppressor cells).
- NK cells are directly cytotoxic to foreign cells (e.g., foreign cancer cells), and do not require complement activity to effect their lysis.
- NK cells represent the body's first line of defense against malignancy.
- B cells produce immunoglobulins, and T cells are involved in modulation of immune responses and in regulation of erythropoiesis.
- Different types of lymphocytes can be distinguished from each other and from other cell types based on the cell type-specific expression of particular molecular markers, generally cell surface markers.
- NK cells bear on their surface CD16 and/or CD56 markers.
- B cells bear at least one of the cell surface markers CD19 and CD20.
- T cells bear one or more of the cell surface markers CD3, CD4, and CD8.
- cytotoxic T cells express CD8, whereas helper T cells express CD4.
- ALC absolute lymphocyte count
- ALC refers to the total number of lymphocytes per unit of whole blood or blood cells in a sample or in a subject (e.g., a human patient).
- a unit can be, for example, a liter (L), milliliter (mL), or microliter ( ⁇ L).
- ALC is measured as the number of mature lymphocytes per ⁇ L, of blood, and includes the cumulative numbers of B cells, T cells, and NK cells.
- Stem cells, lymphocyte precursor cells, and lymphocyte progenitor cells typically are not included in the ALC.
- Stem cells can be differentiated from lymphocytes in that stem cells express the cell surface marker CD34, whereas mature lymphocytes do not.
- lymphocytes express specific cell surface markers as described above (NK cells: CD16 and/or CD56; B cells: CD20 and/or CD19; T cells: CD3, CD4, and/or CD8), whereas stem cells do not express these markers.
- a sample of blood can be collected from a patient.
- blood can be collected in a rubber-stopped tube containing EDTA or another medically acceptable anti-coagulant.
- Blood can be collected using any route of entry to the circulatory system known in the art.
- the blood sample then can be analyzed to determine the ALC.
- an ALC can be obtained using an automated system for counting blood cells in a sample.
- Such cell counting systems typically are based on a principle by which unstained, unlabeled cells are sorted and counted based on morphological characteristics including, without limitation, cell size, cell shape, nuclear size, and nuclear shape.
- the GEN-STM Hematology Analyzer identifies and counts cell types based on three general criteria: volume, conductivity, and scatter (see U.S. Pat. No. 5,125,737).
- a blood sample can be treated before analysis with reagents and/or physical agitation to lyse the RBC, thereby leaving WBC for analysis.
- the Gen-STM Analyzer uses a process of DC impedance by which the cells are collided with light to physically measure the volume displaced by the entire cell in an isotonic diluent. Cell size thus can be accurately determined regardless of the orientation of the cell in the light path.
- Cells can be further collided with an alternating current in the radio frequency range that can permeate cell membranes, such that information can be obtained with regard to internal structure including, for example, chemical composition and nuclear structure.
- a cell can be collided with a laser beam that, upon contacting the cell, scatters and spreads out in all directions, generating median angle light scatter signals. These signals can be collected to yield information regarding cellular granularity, nuclear lobularity, and cell surface structure.
- such a system can count and differentiate RBC from WBC based on the presence or absence of a nucleus, and can count and differentiate the different types of WBC based on the ratio of nuclear to cytoplasmic volume, lobularity of the nucleus, and granularity of the cytoplasm as described below, for example.
- ALC also can be determined by placing a known volume of a blood sample onto a glass microscope slide, smearing the sample to create a thin film of blood on the slide, and staining the sample using standard histological stains such as, for example, hematoxylin and eosin (H & E). Briefly, a blood smear can be dried and subsequently fixed onto a slide using a fixative such as, without limitation, neutral buffered formalin, formaldehyde, paraformaldehyde, glutaraldehyde, Bouin's solution, mercuric chloride, or zinc formalin.
- a fixative such as, without limitation, neutral buffered formalin, formaldehyde, paraformaldehyde, glutaraldehyde, Bouin's solution, mercuric chloride, or zinc formalin.
- the slides then can be immersed in a solution of Harris Hematoxylin, rinsed in water, immersed in a solution of Eosin, rinsed in water, dehydrated in ascending alcohol solutions, and cleared in xylenes.
- nuclei and other basophilic structures stain blue, whereas cytoplasm and other acidophilic structures stain light to dark red (Sheehan et al. (1987) Theory and Practice of Histotechnology, 2nd Edition, Battelle Memorial Institute, Columbus, Ohio), which is incorporated herein by reference in its entirety.
- the number of lymphocytes present in a blood smear can be counted based on lymphocytic morphological criteria accepted in the art.
- the lymphocyte nucleus when stained with H & E, the lymphocyte nucleus is deeply colored (purple-blue) and is composed of dense aggregates of chromatin within a sharply defined nuclear membrane.
- the nucleus generally is round, eccentrically located, and surrounded by a small amount of light blue staining cytoplasm.
- the volume of nucleus to cytoplasm in a lymphocyte typically is about 1:1.2.
- Lymphocytes can be differentiated from RBC in that RBC have no nuclei.
- Lymphocytes can be differentiated from neutrophils in that neutrophils have nuclei with 2 to 5 lobes, while lymphocyte nuclei are not lobed.
- Lymphocytes can be differentiated from basophils and eosinophils in that those cells have cytoplasmic granules, while lymphocytes do not have cytoplasmic granules. Lymphocytes can be differentiated from monocytes in that monocytes are 16 to 20 gm in diameter, while lymphocytes are 7 to 10 um in diameter. In addition, one of skill in the art may refer to any of a number of hematology or histological texts or atlases (e.g., Wheater et al. (1987) Functional Histology 2nd Ed. Churchill Livingstone, incorporated herein by reference in its entirety) to determine the physical appearance of a lymphocyte.
- ALC also can be determined by immunolabeling lymphocytes with antibodies specific for lymphocyte cell surface markers, and counting the immunolabeled cells using fluorescence flow cytometry (FFC).
- FFC fluorescence flow cytometry
- NK cells can be labeled with one or more fluorescently labeled antibodies specific for CD16 and/or CD56.
- B cells can be labeled with one or more fluorescently labeled antibodies specific for the adhesion molecules CD20 and/or CD19
- T cells can be labeled with one or more fluorescently labeled antibodies specific for CD3, CD4, and/or CD8, and.
- cell surface marker-specific antibodies can be labeled with the same fluorophore (e.g., Cy-5, fluorescein, or Texas Red).
- a FFC machine can be adapted for fluorescence activated cell sorting (FACS), i.e., the separation (and collection) of (a) fluorescent cells from non-fluorescent cells; (b) strongly fluorescent cells from weakly fluorescent cells; or (c) cells fluorescing at one wavelength from cells fluorescing at another wavelength.
- FACS fluorescence activated cell sorting
- Monocytes are large phagocytic WBC that have a simple nucleus and clear, grayish cytoplasm. Monocytes can differentiate into macrophages and myeloid lineage dendritic cells.
- Classical monocytes are characterized by high level expression of the CD14 cell surface receptor without expression of the CD16 cell surface receptor, but other populations of monocytes are characterized by low level expression of CD14 and high level expression of CD16, or high level expression of CD14 and low level expression of CD16.
- AMC absolute monocyte count
- a unit can be, for example, a L, mL, or ⁇ L.
- AMC can be determined by, for example, using an automated cell count machine or flow cytometry, as described above with regard to ALC.
- ALC and AMC have been determined, whether the A-ALC and A-AMC in a population of collected stem cells from a patient, or the ALC and AMC in a blood sample obtained from a subject, the ratio of lymphocytes to monocytes can be determined.
- the ratio of A-ALC to A-AMC for a population of autologous cells to be used in APBHSCT is referred to herein as A-LMR, while the ratio of ALC to AMC in a biological sample (e.g., a blood sample) collected from a subject is referred to herein as LMR.
- An A-LMR for a population of collected autologous stem cells that is at least 1.0 (e.g., 1.1, 1.2, 1.3, 1.4, 1.5, 2.0, 2.5, or greater than 2.5) can indicate that the patient receiving the APBHSCT has a greater likelihood of progression-free and overall survival than he/she would if the A-LMR was less than 1.0 (e.g., 0.9, 0.8, 0.7, 0.6, 0.5, or less than 0.5).
- a LMR of at least 1.0 determined for a biological sample e.g., a blood sample obtained from a cancer patient at diagnosis, before or after chemotherapy, or from an APBHSCT recipient after transplant (e.g., 15, 30, 60, or 90 days post-transplant) can indicate that the patient has a greater likelihood of progression-free and overall survival than he/she would if the LMR was less than 1.0.
- NK cells can be collected using an apheresis procedure as described above.
- the number of collected NK cells can be monitored. For example, the number of NK cells can be determined at one or more points during collection of the sample from the patient. The number of NK cells also can be determined after completion of a collection. Once the population of total collected cells includes at least about 0.5 ⁇ 10 9 NK cells/kg, they can be returned to the patient.
- the number of collected CD14+HLA-DR DIM cells also can be determined, and the ratio as compared to NK cells can be determined.
- the number of collected NK cells and CD14+HLA-DR DIM cells can be monitored using methods such as those described above.
- the number of collected NK cells can be determined using immunolabeling with one or more fluorescently labeled antibodies specific for CD16 and/or CD56, and counting with FACS, while the number of collected CD14+HLA-DR DIM cells can be determined using immunolabeling with one or more labeled antibodies specific for CD14 and/or HLA-DR DIM , followed by counting with FACS.
- the ratio of NK cells to CD14+HLA-DR DIM cells can be determined.
- a ratio of NK: CD14+FILA-DR DIM that is at least 0.29 can indicate that the patient receiving the stern cells via APBHSCT has a greater likelihood of progression-free and overall survival than he/she would if the ratio was less than 0.29 (e.g., 0.28, 0.25, 0.23, 0.20, or less than 0.20).
- a NK:CD14+HLA-DR DIM of at least 0.29 determined for a biological sample e.g., a blood sample obtained from a cancer patient at diagnosis, before or after chemotherapy, or from an APBHSCT recipient, post-transplant (e.g., 15, 30, 60, or 90 days post-transplant) can indicate that the patient has a greater likelihood of progression-free and overall survival than he/she would if the NK:CD14+HLA-DR DIM ratio was less than 0.29.
- the methods provided herein also can include treatment of a patient or a cell population (e.g., in a biological sample such as an apheresis product) with one or more agents that stimulate proliferation, maturation, differentiation, function, and/or activity of immune cells (e.g., lymphocytes, including NK cells).
- a patient or a population of collected cells can be contacted with an agent such as IL-2, IL-12, IL-15, IL-17, IL-21, interferon alpha (IFN- ⁇ ), or interferon gamma (IFN- ⁇ ).
- agents can be native factors obtained from a natural source, factors produced by recombinant DNA methodology, chemically synthesized polypeptides or molecules, or any derivative having the functional activity of the native factor. Since agents such as these can enhance the number and/or activity of lymphocytes (e.g., NK cells), a patient may be subjected to shorter or fewer apheresis procedures in order to harvest a cell population containing, for example, an A-LMR or LMR of at least 1.0, and/or an A-NK;A-CD14+HLA-DR DIM of at least 0.29.
- lymphocytes e.g., NK cells
- a population of collected cells can be contacted with an agent or platform that depletes monocytes.
- the population of cells may be identified as having an A-LMR or LMR less than 1.0, or an A-NK;A-CD14+HLA-DR DIM or NK:CD14 ⁇ HLA-DR DIM less than 0.29.
- Suitable methods for depleting monocytes include, for example, contacting a population of cells with a support (e.g., a solid surface such as a bead) coupled to CD14 (e.g., CD14 microbeads; Mitenyi Biotec), and collecting the cells that do not bind to the support.
- a population of cells can be contacted in vitro with one or more agents such as those listed above.
- collected cells can be placed in a vessel (e.g., a bag, a tube, a vial, or any other suitable container) and contacted with one or more agents such as those described above.
- cells can be contacted in vitro with IL-2 at a dose of, for example, about 1.5 ⁇ 10 6 to about 2.0 ⁇ 10 6 units.
- Lymphocyte (e.g., NK cell) enhancing agents can be added to cells within a container such as a bag (e.g., a blood bag), tube, or vial, or such a vessel can contain one or more such agents prior to placement of cells within the vessel.
- a container such as a bag (e.g., a blood bag), tube, or vial, or such a vessel can contain one or more such agents prior to placement of cells within the vessel.
- one or more agents can be dispersed on an inner surface of the vessel.
- an agent in liquid form can be dispersed (e.g., sprayed) onto an inner surface of the vessel and allowed to dry.
- an agent in solid (e.g., lyophilized or powdered) form can be dispersed on an inner surface of the vessel.
- an agent in liquid or solid form can simply be placed within the vessel.
- one or more lymphocyte enhancing agents can be administered to a patient.
- a patient can be treated with such an agent prior to collection of a biological sample containing lymphocytes and monocytes, or a patient can be treated post-APBHSCT.
- the number of NK cells in the PB of a patient can be monitored following APBHSCT, and a NK cell enhancing agent can be administered to the patient if the number of NK cells is below a particular threshold at a particular time point (e.g., at post-transplant day 15).
- a suitable threshold can be, for example, about 80 NK cells/ ⁇ L of blood (e.g., about 75 NK cells/ ⁇ L or about 85 NK cells/ ⁇ L).
- a NK cell enhancing agent can be administered to a patient post-APBHSCT if the ALC-15 is less than 500 cells/ ⁇ L of blood.
- Agents such as those listed above can be administered to a patient via any pharmaceutically acceptable route known in the art, including, for example, intravenous injection, intra-arterial injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, or oral administration in the form of a tablet, capsule, or syrup.
- IL-2 can be administered to a patient prior to collection of autologous cells, or after APBHSCT.
- a patient can be treated with IFN- ⁇ at a concentration of, for example, between about 1 ⁇ 10 5 and about 1 ⁇ 10 7 units/m 2 .
- the agent(s) can be administered from the day of transplant up to about 21 days following the transplant.
- patients or collected cell populations also can be treated with one or more agents that activate the T cell signal transduction pathway, leading to lymphocyte activation.
- a T cell activator can be, without limitation, one or more of the following: IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, IL-13, IFN ⁇ , IFN ⁇ , tumor necrosis factor (TNF ⁇ ), an anti-CD3 antibody or antigen-binding fragments thereof (anti-CD3), an anti-CD28 antibody or antigen-binding fragments thereof (anti-CD28), phytohemagglutinin, concanavalin-A, and phorbol esters.
- these agents can be native factors obtained from a natural source, factors produced by recombinant DNA methodology, chemically synthesized polypeptides or molecules, or any derivative having the functional activity of the native factor.
- Example 1 A-LMR as a predictor of survival
- FIGS. 1 A and 1 B An A-LMR of 1 or higher correlated with increased overall survival ( FIGS. 1 A and 1 B, top panels), increased progression-free survival ( FIGS. 1 A and 1 B , middle graphs), and increased lymphoma-specific survival ( FIGS. 1 A and 1 B , bottom graphs), while an A-LMR less than 1 correlated with decreased overall survival ( FIGS. 1 A and 1 B , top panels), decreased progression-free survival ( FIGS.
- FIGS. 1 A and 1 B middle graphs
- FIGS. 1 A and 1 B bottom graphs
- Example 2 A-NK:A-CD14+HLA-DR DIM as a predictor of survival
- a double-blind, phase III, randomized clinical trial was conducted to determine whether A-NK:A-CD14+HLA-DR DIM can be used as a predictor of survival in 111 non-Hodgkin's lymphoma (NHL) patients.
- the primary end point of was to assess the impact of A-NKC/ACD14 + HLA-DR DIM ratio on overall survival (OS) and progression-free survival (PFS).
- a secondary end point was to determine whether the A-NKC/A-CD14 + HLA-DR DIM ratio is an independent prognostic factor for OS and PFS.
- IPI International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma.,” N Engl J Med 1993, 329:987-994
- LDH lactate de
- BCNU carmustine, 300 mg/m 2
- Etoposide 100 mg/m 2
- ARA-C Cytarabine, 100 mg/m 2
- Melphalan 140 mg/m 2
- OS was measured from the date of APBHSCT to the date of death or last follow-up
- PFS was defined as the time from APBHSCT to time of progression, relapse, death or last follow-up (Cheson et al. 2007, J Gin Oncol 25:579-586).
- Previously frozen autograft mononuclear cells (0.5-1.0 ⁇ 10 6 cells/mL) were thawed and aliquoted into 96-well round-bottomed plates (100 mL/well).
- the following monoclonal antibodies were used for autograft mononuclear cell immunophenotyping by flow cytometry: anti-human CD3 FITC, anti-human CD16 phycoerythrin (PE), and anti-human CD56 PE for NK cells, and anti-human CD14 FITC and anti-human HLA-DR PE-cyanin 5.5 (PE-Cy5.5) for HLA-DR dim monocytes (BD Pharmingen; San Jose, Calif.).
- the desired antibody or antibody pool was added at 5 uL of each antibody/well.
- the cells and antibodies were incubated for 30 minutes at 4° C. and washed twice with 1 x PBS (Cellgro; Manassas, Va.), 0.1% BSA and 0.05% sodium azide (Sigma; St Louis, Mo.). Three-color flow cytometry was performed on a Guava 8-HT (Millipore; St Louis, Mo.) and Incyte software (Millipore) was utilized for data analysis. After gating on live lymphocytes, the percentage of NK cells was determined by the number of cells that were CD3 negative and CD16 and CD56 positive. For the HLA-De DIM cells, gates were set on live cells, and CD14-positive cells and HLA-DR DIM cells were enumerated from the CD14-positive gate.
- the absolute numbers of autograft NK cells and autograft CD14 + HLA-DR DIM cells were calculated by multiplying their percentage times the A-ALC for NK cells and autograft absolute monocyte count (A-AMC) for CD14 + FILA-DR DIM cells for each apheresis unit collection.
- OS and PFS were analyzed using the approach of Kaplan-Meier (Kaplan and Meier 1958, J A117 Stat Assoc 53:457-481). Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. Univariate and multivariate analysis was performed using Cox proportional hazard model (Cox 1972, J R Stat Soc 34:187-202). The variables in the prognostic factor section were evaluated to assess their impact on OS and PFS times post APBHSCT.
- the choice of the cutoff value for the A-NKC/A-CD14 +HLADR DIM ratio to assess survival was based on its utility as a marker for the clinically relevant binary outcome of death/survival using the receiver operating characteristics curves (ROC) and area under the curve (AUC).
- the binary clinical outcome (death/survival) was established at 5 years after APHSCT. Patients were classified as ‘alive/censored’ when follow-up time was >5 years and ‘death/uncensored’ for patients known to have died before this time point (Tzankov et al. 2010, Leak Lymphoma 51:199-212).
- a K-fold cross-validation with K-values of 10 was performed to validate the results of A-NKC/ACDl4 4 HLADRDTM ratio cutoff obtained by the ROC and AUC curves.
- the median age at the time of APBHSCT was 57 years (range: 20-74).
- the distribution of additional baseline characteristics for this cohort is presented in TABLE 1.
- the day-100 transplantation-related mortality was 1.8% (2/111): one patient died because of septic shock and one patient died of acute respiratory distress syndrome.
- FACS fluorescence-activated cell sorting
- the cross-validation ROC showed an AUC of 0.66 (95% CI, 0.66-0.72); for A-CD1411LA-DR DIM , an AUC of 0.76 (95% CI, 0.71-0.81); and for A-NK:ACD141-1LA-DR DIM . ratio, an AUC of 0.76 (96% CI, 0.70-0.82) ( FIG. 3 B ).
- AUC from the empirical ROC and the cross-validation ROC curves support the use of A-NKC >0.09 ⁇ 10 9 cells/kg, A-CD141-ILA-DR DIM ⁇ 0.21 ⁇ 10 9 cells/kg, and the A-NK:A-CD 14 + HLADR DIM ratio of>0.29 for cutoff values as markers of the binary clinical outcome of death/survival.
- A-NK:A-CD14 ⁇ ′HLA-DR DIM ratio >0.29 was a predictor for OS and PFS (see, TABLES 2A and 2B).
- the first multivariate analysis included A-NKC and A-CD14 ⁇ ′HLA-DR DTM with the other prognostic factors in TABLES 2A and 2B, excluding the A-NK:A-CD1411LA-DR DIM ratio.
- A-NKC and A-CD1441LA-DR DIM were excluded, and the A-NK:A-CD14′HLA-DR DIM ratio was included in the analysis.
- A-CD14 ⁇ FILA-DR DIM >0.21 ⁇ 10 9 cells/kg and A-NK:A-CD1441LA-De lm ratio >0.29 were tested for OS and PFS.
- patients infused with an A-CD14 4- HLA-DR DIm 0.21 ⁇ 10 9 cells/kg experienced superior OS ( FIG. 4 A ) and PFS ( FIG. 4 B ): median OS of not reached vs.
Abstract
Provided herein are materials and methods for assessing ratios of lymphocyte to monocytes in cancer patients and, based on the ratios, treating the cancer patients with an immunotherapeutic.
Description
- This application is a divisional of U.S. application Ser. No. 16/486,863, filed Aug. 19, 2019, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2018/018744, having an International Filing Date of Feb. 20, 2018, which claims benefit of priority from U.S. Provisional Application Ser. No. 62/461,663, filed Feb. 21, 2017. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.
- This document relates to materials and methods for assessing the lymphocyte to monocyte ratio (LMR) in cancer patients, and for treating cancer patients an immunostimulatory agent when the LMR is at least 1.0.
- Autologous peripheral blood hematopoeitic stern cell transplantation (APBHSCT) can improve survival in various types of cancer, including myelomas and leukemias [e.g., acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)], as well as Hodgkin and non-Hodgkin's lymphomas [e.g., diffuse large B-cell lymphoma (DLBCL)], whether the APBHSCT is carried out before, after, or without chemotherapy.
- High relapse rates post-APBHSCT, however, have been attributed to the inability of high dose therapy (HDT) to eradicate minimal residual disease. In contrast, allogeneic stem cell transplantation following chemotherapy results in lower relapse rates, which have been correlated to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-versus-tumor effect in the recipient (Kersey et al. (1987) New Engl J Med 317:416; Marmont et al. (1991) Blood 78:2120). Allogeneic stem cell transplantation has also, however, been associated with a higher incidence of graft-versus-host disease (GVHD), thus leading to higher allogeneic transplant-related mortality in comparison to APBHSCT.
- This document is based, at least in part, on the discovery that the lymphocyte to monocyte ratio in infused autologous stem cell transplants (A-LMR), as well as the lymphocyte to monocyte ratio (LMR) achieved in patients treated by APBHSCT, can be used as an indicator of prognosis, and also as the impetus for treating a transplant recipient with an immunostimulatory agent [e.g., interleukin-15 (IL-15) or interleukin-21 (IL-21), or a combination thereof]. For example, a LMR that is less than 1.0 can be used as an indicator that a patient has a worse prognosis than a patient with a LMR of 1.0 or greater (e.g., such that the patient with a LMR less than 1.0 has a lower chance of progression-free survival or overall survival than a patient with a LMR of at least 1.0). The LMR also can be used as an indicator that a patient should be treated with an immunotherapeutic that can increase the absolute lymphocyte count (ALC) in the patient, reduce the absolute monocyte count (AMC) in the patient, or both.
- In addition, this document is based, at least in part, on the discovery that the autograft absolute monocyte count (A-AMC) in infused autologous stem cell transplants (A-AMC), as well as the AMC recovery post-APBHSCT, can be used as an indicator of prognosis. For example, a patient receiving APBHSCT having an A-AMC that is more than 0.5×109 cells/kg may have a worse prognosis than a patient receiving APBHSCT having an A-AMC of 0.5×109 cells/kg or less. In some cases, an A-AMC greater than 0.5×109 cells/kg can indicate that the stem cell preparation should be treated to deplete immunosuppressive monocytes before being administered to the patient. For example, a population of collected autologous cells can be passed through a CD14 microbead column (Mitenyi Biotec; Bergisch Gladbach, Germany) to reduce the number of monocytes in the population before the cells are returned to the patient.
- Further, this document is based, at least in part, on the discovery that the ratio of natural killer (NK) cells to CD14+HLA-DRDIM myeloid-derived monocytic cells in a population of autologous stem cells to be infused (A-NK:A-CD14+HLA-DRDIM), as well as the CD14+HLA-DRDIM cell count in a population of autologous stern cells to be infused, can be used as indicators of prognosis. For example, a patient receiving APBHSCT with an A-NK:A-CD14+HLA-DRDIM less than 0.29, or a CD14+HLA-DRDIM count greater than or equal to 0.21×109 cells/kg, may have a worse prognosis than a patient receiving APBHSCT with an A-NK:A-CD14+HLA-DeDIM of 0.29 or greater, or a CD14+HLA-DRDTM count less than 0.21×109 cells/kg (e.g., such that the patient receiving the transplant with an A-NK:A-CD14+HLA-DRDIMless than 0.29 has a lower chance of progression-free survival or overall survival than a patient receiving APBHSCT with an A-NK:A-CD14+HLA-DRDIM of at least 0.29). In some cases, an A-NK:A-CD14+HLA-DRDIM of 0.29 or less can be an indicator that the stern cell preparation should be treated to deplete monocytes or increase NK numbers prior to transfer to the patient.
- Using the methods and materials provided herein can allow clinicians to identify patients who may benefit from treatment with an immunotherapeutic such as IL-15, IL-21, and/or a monocyte depleting agent. Once identified as having a ratio of lymphocytes to monocytes, a CD14+HLA-DRDIM count, or a ratio of NK cells to CD14+HLA-DRDIM cells, that suggests a poor prognosis, a patient can be administered an agent (e.g., IL-15, IL-21, and/or a monocyte depleting agent) to and improve the patient's prognosis.
- In one aspect, this document features a method for treating a cancer patient, where the method includes (a) identifying the patient as having a biological sample with a LMR less than 1.0; and (b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent. The immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21. The LMR can have been determined at initial diagnosis of the cancer. The patient can be a subject who was or is to be treated with APBHSCT, and the LMR can have been determined using A-ALC and A-AMC in the APBHSCT sample prior to transfer. The patient can be a subject who has received an APBHSCT, and the LMR can have been calculated using ALC and AMC in a blood sample obtained from the patient after the APBHSCT (e.g., 15 days after the APBHSCT). The patient can be a subject treated with chemotherapy, and the LMR can have been calculated using ALC and AMC within a blood sample obtained from the patient after the chemotherapy (e.g., 15 days after the chemotherapy). The chemotherapy can include treatment with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP), and a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer. The can include identifying the patient as having a LMR less than 0.9, and administering a pharmaceutical composition comprising IL-15, IL-21, or a combination of IL-15 and IL-21. The method can include administering IL-15 and IL-21 simultaneously, or administering IL-15 and IL. 21 separately. The method can further include conducting a positron emission tomography (PET) scan on the patient.
- In another aspect, this document features a method for treating a cancer patient, where the method includes (a) identifying the patient as having a biological sample with a natural killer (NK):CD14+HLA-DRD″ ratio less than 0.29; and (b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent. The immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21. The NK:CD14+HLA-DRDIM ratio can have been determined at initial diagnosis of the cancer. The patient can be a subject who was or is to be treated with APBHSCT, and the NK:CD14+HLA-DRDTM ratio can have been determined using absolute NK cell count and absolute CD14+HLA-DRDIM count in the APBHSCT sample prior to transfer. The patient can be a subject who has received an APBHSCT, and the NK:CD14+HLA-DRDIM ratio can have been calculated using absolute NK cell count and absolute CD14+HLA-DRDIM count in a blood sample obtained from the patient after the APBHSCT (e.g., 15 days after the APBHSCT). The patient can be a subject who was treated with chemotherapy, and the NK cell count can have been calculated using absolute NK cell count and absolute NK:CD14+HLA-DRDIM count within a blood sample obtained from the patient after the chemotherapy (e.g., 15 days after the chemotherapy). The chemotherapy can include treatment with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD. The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer. The method can include identifying the patient as having a NK:CD14+HLA-DRDIM ratio less than 0.25, and administering a pharmaceutical composition comprising IL-15, IL-21, or a combination of IL-15 and IL-21. The method can include administering IL-15 and IL-21 simultaneously or separately. The method can further include conducting a PET scan on the patient.
- In another aspect, this document features a method for identifying a cancer patient as having an increased likelihood of survival, where the method includes (a) determining that a biological sample containing cells from the patient has a LMR of at least 1.0 or a NK:CD14±HLA-DRDIM of at least 0.29; and (b) classifying the patient as having an increased likelihood of survival, as compared to a patient having a LMR less than 1.0 or a NK;CD14+HLA-DRDIM less than 0.29. The biological sample can contain autologous stem cells collected via an apheresis procedure. The biological sample can be a blood sample obtained from the patient before or after treatment with chemotherapy or APBHSCT. The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- The patient can be a subject who has been treated with chemotherapy or APBHSCT, and the survival can be progression-free survival.
- In still another aspect, this document features a method for identifying a cancer patient as having a decreased likelihood of survival, where the method includes (a) determining that a biological sample containing cells from the patient has a LMR less than 1.0 or a NK:CD14±HLADRDIM less than 0.29; and (b) classifying the patient as having a decreased likelihood of survival, as compared to a patient having a LMR of at least 1.0 or a NK:CD14+HLA-DRDIM of at least 0.29. The biological sample can contain autologous stem cells collected via an apheresis procedure. The biological sample can be a blood sample obtained from the patient before or after treatment with chemotherapy or APBHSCT. The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer esophageal cancer, gastric cancer, and pancreatic cancer. The patient can be a subject who has been treated with chemotherapy or APBHSCT, and the survival can be progression-free survival.
- This document also features a method for treating a population of autologous cells collected from a cancer patient, where the method includes (a) determining that the population of cells has a LMR less than 1.0 or a NK:CD14+HLA-DRDIM less than 0.29; and (b) contacting the population of cells with an agent that depletes monocytes. The agent can include a support coupled to CD14.
- In yet another aspect, this document features a method for treating a cancer patient, where the method includes (a) identifying the patient as having a biological sample as containing an A-CD14′HLA-DRDIM cell count that is greater than or equal to 0.21×109 cells/kg; and (b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent. The immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21. The number of A-CD1441LA-DRDIM cells can have been determined at initial diagnosis of the cancer. The patient can be a subject who was or is to be treated by APBHSCT, where the A-CD14+HLA-DR DIM count was determined using absolute CD14+HLA-DRDIM count in the APBHSCT sample prior to transfer. The patient can have received an APBHSCT, where the A-CD14 +HLA-DRDIM count was calculated using absolute CD14+HLA-DRDIM count in a blood sample obtained from the patient after the APBHSCT. The blood sample can have been obtained 15 days after the APBHSCT. The patient can be a subject who was treated with chemotherapy, where the LM A-CD14′HLA-DRDIM count was calculated using absolute A-CD14+HLA-DRDIM count within a blood sample obtained from the patient after the chemotherapy (e.g., 15 days after the chemotherapy). The chemotherapy can have included one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD. The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer. The method can further include conducting a PET scan on the patient.
- In addition, this document features the use of a pharmaceutical composition containing an immunotherapeutic agent for treating a cancer patient, where the cancer patient is identified as having a biological sample with a LMR less than 1.0. The immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21. The LMR can have been determined at initial diagnosis of the cancer. The patient can be a subject who was or is to be treated by APBHSCT, where the LMR was determined using absolute lymphocyte count and absolute monocyte count in the APBHSCT sample prior to transfer. The patient can be a subject who has received an APBHSCT, where the LMR was calculated using absolute lymphocyte count and absolute monocyte count in a blood sample obtained from the patient after (e.g., 15 days after) the APBHSCT. The patient can be a subject who was treated with chemotherapy, where the LMR was calculated using absolute lymphocyte count and absolute monocyte count within a blood sample obtained from the patient after (e.g., 15 days after) the chemotherapy. The chemotherapy can include treating with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD. The cancer can be is selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer. The patient can be identified as having a LMR less than 0.8.
- In another aspect, this document features the use of a pharmaceutical composition containing an immunotherapeutic agent for treating a cancer patient identified as having a biological sample with a NK:CD14+HLA-DRD″ ratio less than 0.29. The immunotherapeutic agent can be IL-15, IL-21, or a combination of IL-15 and IL-21. The NK:CD14+HLA-DRDIM ratio can have been determined at initial diagnosis of the cancer. The patient can be a subject who was or is to be treated by APBHSCT, where the NK:CD14+HLA-DRDIM ratio was determined using absolute NK cell count and absolute CD14+HLA-DRDTM count in the APBHSCT sample prior to transfer. The patient can be a subject who has received an APBHSCT, where the NK:CD14+HLA-DRDIM ratio was calculated using absolute NK cell count and absolute CD14+HLA-DRDIM count in a blood sample obtained from the patient after (e.g., 15 days after) the APBHSCT. The patient can be a subject who was treated with chemotherapy, where the NK:CD14+HLA-DRDIM ratio was calculated using absolute NK cell count and absolute CD14-FHLA-DRDIM count within a blood sample obtained from the patient after (e.g., 15 days after) the chemotherapy. The chemotherapy can include treating with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD. The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer. The cancer patient can be identified as having a NK:CD14+HLA-DRDIM ratio less than 0.25.
- In still another aspect, this document features the use of a pharmaceutical composition containing an immunotherapeutic agent for treating a cancer patient identified as having a biological sample as containing an A-CD14−′HLA-DRDIM cell count greater than or equal to 0.21×109 cells/kg. The immunotherapeutic agent can be IL-15, 1L-21, or a combination of IL-15 and IL-21. The number of A-CD14−′HLA-DRDim cells can have been determined at initial diagnosis of the cancer. The patient can be a subject who was or is to be treated by APBHSCT, where the A-CD1411LA-DRDIM count was determined using absolute CD14+HLA-DRDIM count in the APBHSCT sample prior to transfer. The patient can be a subject who received an APBHSCT, where the A-CD14 +HLA-DRDIM count was calculated using absolute CD14+HLA-DRDIM count in a blood sample obtained from the patient after (e.g., 15 days after) the APBHSCT. The patient can be a subject who was treated with chemotherapy, where the LM A-CD1441LA-DRDIM count was calculated using absolute A-CD14′11LA-DRDIM count within a blood sample obtained from the patient after (e.g., 15 days after) the chemotherapy. The chemotherapy can include treating with one or more of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, RCHOP, and ABVD. The cancer can be selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, and non-Hodgkin's lymphoma, or selected from the group consisting of breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
-
FIGS. 1A and 1B are a series of Kaplan-Meier plots showing overall survival (top), progression-free survival (middle), and lymphoma-specific survival (bottom) for DLBCL patients treated with APBHSCT, using a population of autologous cells having an A-LMR of 1 or greater, or less than 1, as indicated. -
FIGS. 2A-2E are a series of fluorescence-activated cell sorting (FACS) scatter plots.FIG. 2A , autograft lymphocytes were gated on a forward scatter (FSC)/side scatter (SSC) plot.FIG. 2B , autograft natural killer cells (CD16+, CD56+, CD3−) were enumerated from the lymphocyte-positive gate.FIG. 2C , autograft monocytes were gated on a FSC/SSC plot.FIG. 2D , autograft monocytes were further gated to determine CD14+cells.FIG. 2E , autograft CD14±HLA-Delm were enumerated from the CD14′ gate. -
FIGS. 3A and 3B are graphs plotting the Receiver Operating Characteristic (ROC) and area under the curve (AUC) for A-NK:A-CD14÷HLA-DRDIM ratio.FIG. 3A , ROC and AUC for A-NK:A-CD14+1-1LA-DRDIM >0.29 with an AUC=0.75, 95% CI, 0.70-0.80, P<0.0003.FIG. 3B , K-fold cross-validation ROC and AUC for A-NK:A-CD1411LA-DRDIM with an AUC=0.76, 95% CI, 0.70-0.82. -
FIGS. 4A-4D are a series of Kaplan-Meier plots showing, OS or PFS for non-Hodgkin lymphoma patients treated with APBHSCT using various populations of autologous cells.FIG. 4A , OS for A-CD14+HLA-DRDIM<0.21×109 cells/kg vs. A-CD14′HLA-DRDIM >0.21×109 cells/kg.FIG. 4B , PFS for A-CD14÷HLA-DRD1m<0.21×109 cells/kg vs. A-CD141-ILA-DRDIM >0.21×109 cells/kg.FIG. 4C , OS for A-NK:A-CD14+FILA-DRDIM ratio >0.29 vs. A-NK:A-CD141-ILA-DRDIM ratio <0.29.FIG. 4D , PFS for A-NK:A-CD14′11LA-DRDIM ratio >0.29 vs. A-NK:A-CD141-ILA-DRDIM ratio <0.29. - This document provides materials and methods that for treating cancer patients, and is based, at least in part, on the discoveries that A-LMR and LMR, as well as A-AMC, AMC, and A-NK:A-CD14+HLA-DRDIM, can be powerful indicators of cancer patient prognosis. Thus, this document provides materials and methods for obtaining a population of stem cells and/or treating a patient to achieve an A-LMR or a LMR of at least 1.0, as well as materials and methods for obtaining a population of stern cells and/or treating a patient to achieve an A-NK:A-CD14+HLA-DRDIM or NK:CD14+HLA-DRDIM of at least 0.29.
- In some embodiments, a subject treated according to the methods described herein can be a human cancer patient diagnosed with, for example, non-Hodgkin lymphoma, Hodgkin's disease, classical Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, or acute lymphoblastic leukemia, or a solid tumor such as a breast tumor, lung tumor, ovarian tumor, liver tumor, or kidney tumor. The methods provided herein can include the step of returning a population of collected autologous cells to the patient. The cell population can be returned to the patient by, for example, intravenous infusion or any other suitable method known in the art. In some embodiments, the patient can be in remission from the cancer, either prior to collection of the cells or prior to returning the cells to the patient.
- As used herein, “autologous” as it relates to transplantation refers to a graft in which the donor and recipient is the same individual. Thus, in an autologous transplant cells are harvested from a subject and then returned to the same subject. In contrast, an “allogeneic” transplant refers to a graft in which the donor and recipient are genetically non-identical individuals from the same species. A “xenogeneic” transplant refers to a graft in which the donor and recipient are of different species.
- As used herein, an APBHSCT refers to a procedure in which a sample of a subject's own stem cells are removed and subsequently transplanted back into the same subject. Stem cells can be harvested from bone marrow (BM) or peripheral blood (PB), for example. Once obtained, stem cells can be frozen until needed. For example, stem cells can be obtained from a patient, cryopreserved at temperatures ≤−85° C., and then thawed and returned (i.e., transplanted, typically by transfusion) to the patient. In some embodiments, stem cell aliquots can be thawed, loaded into one or more sterile syringes or infusion bags, and injected intravenously over a period of time ranging from about 30 minutes to about 45 minutes.
- In some embodiments, stem cells capable of reconstituting a patient's immune system can be obtained from the patient's peripheral circulation following mobilization of such cells from BM into PB. Mobilization of stem cells can be accomplished by treatment of a patient with one or more factors that can (i) stimulate an increase in proliferation of stem cells and/or progenitor cells, and/or (ii) stimulate migration of stem cells and/or progenitor cells from the BM into the peripheral circulation. Such factors can be administered with adjuvants and/or other accessory substances, separately or in combination as desired. Examples of factors that can be used in this aspect include, without limitation, granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), c-kit ligand (stem cell factor (SCF)), interleukin-2, -7, -8, and -12 (IL-2, IL-7, IL-8, and IL-12), and flt-3 ligand. See, e.g., Bungart et al. (1990) Br. J. Haernatol. 76:174; Terella et al. (1993) Bone Marrow Transplant. 11:271; Molineux et al. (1991) Blood 85:275; Grzegorzewski et al. (1994) Blood 83:377; Laterveer et al. (1995) Blood 85:2269; Jackson et al. (1995) Blood 85:2371; and Lyman et al. (1994) Blood 83:2795. Factors to be administered can include, for example, G-CSF alone (e.g., 10 ug/kg/day G-CSF), G-CSF+flt-3 ligand (e.g., 10 ug/kg/day G-CSF+50 mg/kg/day flt-3 ligand), or GM-CSF+flt-3 ligand (e.g., 5 μg/kg/day GM-CSF+50 ug/kg/day flt-3 ligand). See, e.g., Sudo et al. (1997) Blood 89:3186. Such factors can be administered prior to harvest or starting on the day of harvest, for example, and can be given on a daily basis for one to seven days (e.g., for one, two, three, four, five, six, or seven days), or until stern cell harvesting is complete. Factors that stimulate stern cell proliferation or mobilization can be administered using any suitable method. Typically, such factors can be administered parenterally (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip). Mobilization of stem cells with, for example, GM-CSF and flt-3 ligand can be evaluated by determining the number of CD34+ cells present before, during, and/or after treatment with one or more mobilizing agents. In some embodiments, the number of CD34+ cells can be determined by FACS analysis using CD34-specific antibodies conjugated to fluorescent or other labeling moieties.
- Following or during mobilization, peripheral blood stem cells (PBSC) can be collected using, for example, an apheresis procedure. The process of apheresis, which is well known in the art, involves removal of whole blood from a patient or donor. Within an instrument that is essentially designed as a centrifuge, the components of the whole blood are separated. One or more of the separated portions is then withdrawn, and the remaining components can be retransfused into the patient or donor. Thus, for example, all or most (e.g., 80%, 90%, 95%, 99%, or 100%) of the erythrocytes in a sample of whole blood can be returned to a patient during an apheresis procedure, while lymphocytes (e.g., NK cells) and stem cells can be collected. Apheresis can be performed as many as four times per week (e.g., one, two, three, or four times per week). In some embodiments, a commercially available blood cell collection device can be used, such as the CS3000® blood cell collection device or the Fenwal Amicus collection device, both of which are marketed by the Fenwal Division of Baxter Healthcare Corporation (Fenwal Laboratories, Deerfield, Ill.). Methods for performing apheresis with these machines are described in Williams et al. (1990) Bone Marrow Transplantation 5:129-133; Hillyer et al. (1993) Transfusion 33:316-321; and Porrata et al. (2016) Biol Blood Marrow Transplant 22:1017-1023, for example, all of which are incorporated herein by reference in their entirety.
- In some embodiments, a total blood volume between 9.5 and 10 L per apheresis procedure can be processed at a flow rate of 50 to 90 mL/min. Following collection, a cell count can be performed on an aliquot of the total product to determine the number of stein cells. Cells can be collected until the total sample taken from the patient reaches a concentration of at least 2×106 CD34′ stein cells/kg (e.g., 2×10′ CD34′ cell/kg to 3×10′ CD34′ cells/kg, 2×106 CD34′; cells/kg to 2.5×106 CD34−′ cells/kg, or 2.5×106 CD34′ cell/kg to 3×106 CD34′ cells/kg).
- Despite various methods of PBSC mobilization, adequate numbers of PBSC for APBHSCT may be not collected from some patients during a single apheresis procedure. In these patients, BM harvest or a second attempt at PBSC mobilization can be performed. Alternatively, these patients may be excluded from proceeding to APBHSCT.
- Apheresis products can be centrifuged (e.g., at 400 g for 10 minutes), and the plasma can be removed to yield a total volume of, for example, about 100 mL. The resulting cell suspension can be mixed with a physiological freezing solution [e.g., 100 mL minimal essential medium such as MEM-S(Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 20% dimethylsulfoxide (DMSO)]. Cell/media suspensions can be transferred to freezing bags (such as those manufactured by Delmed, Canton, Mass.) or any other freezing receptacle known in the art, and frozen to −100° C. using, for example, a computer-controlled cryopreservation device (e.g., the Cryoson-BV-6; Cryoson Deutschland GmbH, FRG). The cells then can be transferred into liquid nitrogen and stored at until transplantation.
- Patients typically undergo a pre-transplant workup to evaluate, for example, heart, liver, kidney, and lung function, as well as current disease status. In some embodiments, patients deemed to be eligible (e.g., healthy enough) for APBHSCT are subjected to a tumor debulking procedure prior to APBHSCT. For example, a patient can be treated with high doses of chemotherapy, radiation therapy, and/or surgery (e.g., surgery with anesthesia) before the transplant. Stern cells for transplant typically are collected prior to tumor debulking regimens, since such potentially lethal procedures can be immunosuppressive and can severely damage or destroy the BM. APBHSCT following a debulking procedure can reconstitute the patient's immune cells with stem cells present in the transplant.
- In some embodiments, a patient's stem cells can be collected by BM harvest using procedures known in the art, or by a stem cell apheresis procedure as described above, for example. Collected stem cells can be cryopreserved, and the patient can undergo a debulking procedure such as high-dose chemotherapy and/or radiation therapy. After the debulking procedure is completed, the patient's stem cells can be transplanted. APBHSCT can be done almost immediately after a debulking procedure (e.g., 24 to 48 hours after HDT). Alternatively, a longer period of time (e.g., a week to several months) can elapse between a debulking procedure and APBHSCT. Due to the likelihood of immunosuppression as a result of the debulking procedure, protective isolation precautions generally are taken after APBHSCT at least until the reinfused stem cells begin to engraft. “Engraftment” refers to a process whereby the transplanted stem cells begin to differentiate into mature blood cells. In addition, stem cells can be treated prior to transplantation with, for example, anticancer drugs or antibodies to reduce the number of cancerous cells that may be present in the sample. Such procedures are referred to as “purging.”
- In some embodiments of the methods provided herein, subjects (e.g., cancer patients) can be treated by administration of autologous cell populations that contain stem cells and other cell types, including, for example, red blood cells (RBC), lymphocytes, and monocytes. Lymphocytes are white blood cells (WBC) that are formed in lymphatic tissue throughout the human body (e.g., lymph nodes, spleen, thymus, tonsils, Peyer's Patches, and bone marrow). In normal adults, lymphocytes comprise approximately 22% to 28% of the total number of leukocytes in the circulating blood. As used herein, the term “lymphocyte” includes NK cells, B cells, and T cells (e.g., T helper cells, cytotoxic T cells, and T suppressor cells). NK cells are directly cytotoxic to foreign cells (e.g., foreign cancer cells), and do not require complement activity to effect their lysis. NK cells represent the body's first line of defense against malignancy. B cells produce immunoglobulins, and T cells are involved in modulation of immune responses and in regulation of erythropoiesis. Different types of lymphocytes can be distinguished from each other and from other cell types based on the cell type-specific expression of particular molecular markers, generally cell surface markers. For example, NK cells bear on their surface CD16 and/or CD56 markers. B cells bear at least one of the cell surface markers CD19 and CD20. T cells bear one or more of the cell surface markers CD3, CD4, and CD8. Typically, cytotoxic T cells express CD8, whereas helper T cells express CD4.
- As used herein, the term “absolute lymphocyte count” (ALC) refers to the total number of lymphocytes per unit of whole blood or blood cells in a sample or in a subject (e.g., a human patient). A unit can be, for example, a liter (L), milliliter (mL), or microliter (μL). Typically, but not always, ALC is measured as the number of mature lymphocytes per μL, of blood, and includes the cumulative numbers of B cells, T cells, and NK cells. Stem cells, lymphocyte precursor cells, and lymphocyte progenitor cells typically are not included in the ALC. Stem cells can be differentiated from lymphocytes in that stem cells express the cell surface marker CD34, whereas mature lymphocytes do not. Moreover, lymphocytes express specific cell surface markers as described above (NK cells: CD16 and/or CD56; B cells: CD20 and/or CD19; T cells: CD3, CD4, and/or CD8), whereas stem cells do not express these markers.
- To determine an ALC, a sample of blood can be collected from a patient. For example, blood can be collected in a rubber-stopped tube containing EDTA or another medically acceptable anti-coagulant. Blood can be collected using any route of entry to the circulatory system known in the art. The blood sample then can be analyzed to determine the ALC. In some embodiments, an ALC can be obtained using an automated system for counting blood cells in a sample. Such cell counting systems typically are based on a principle by which unstained, unlabeled cells are sorted and counted based on morphological characteristics including, without limitation, cell size, cell shape, nuclear size, and nuclear shape. For example, the GEN-S™ Hematology Analyzer identifies and counts cell types based on three general criteria: volume, conductivity, and scatter (see U.S. Pat. No. 5,125,737). A blood sample can be treated before analysis with reagents and/or physical agitation to lyse the RBC, thereby leaving WBC for analysis. The Gen-S™ Analyzer uses a process of DC impedance by which the cells are collided with light to physically measure the volume displaced by the entire cell in an isotonic diluent. Cell size thus can be accurately determined regardless of the orientation of the cell in the light path. Cells can be further collided with an alternating current in the radio frequency range that can permeate cell membranes, such that information can be obtained with regard to internal structure including, for example, chemical composition and nuclear structure. A cell can be collided with a laser beam that, upon contacting the cell, scatters and spreads out in all directions, generating median angle light scatter signals. These signals can be collected to yield information regarding cellular granularity, nuclear lobularity, and cell surface structure. Thus, such a system can count and differentiate RBC from WBC based on the presence or absence of a nucleus, and can count and differentiate the different types of WBC based on the ratio of nuclear to cytoplasmic volume, lobularity of the nucleus, and granularity of the cytoplasm as described below, for example.
- ALC also can be determined by placing a known volume of a blood sample onto a glass microscope slide, smearing the sample to create a thin film of blood on the slide, and staining the sample using standard histological stains such as, for example, hematoxylin and eosin (H & E). Briefly, a blood smear can be dried and subsequently fixed onto a slide using a fixative such as, without limitation, neutral buffered formalin, formaldehyde, paraformaldehyde, glutaraldehyde, Bouin's solution, mercuric chloride, or zinc formalin. The slides then can be immersed in a solution of Harris Hematoxylin, rinsed in water, immersed in a solution of Eosin, rinsed in water, dehydrated in ascending alcohol solutions, and cleared in xylenes. In blood smears that have been stained using H & E, nuclei and other basophilic structures stain blue, whereas cytoplasm and other acidophilic structures stain light to dark red (Sheehan et al. (1987) Theory and Practice of Histotechnology, 2nd Edition, Battelle Memorial Institute, Columbus, Ohio), which is incorporated herein by reference in its entirety. The number of lymphocytes present in a blood smear can be counted based on lymphocytic morphological criteria accepted in the art.
- For example, when stained with H & E, the lymphocyte nucleus is deeply colored (purple-blue) and is composed of dense aggregates of chromatin within a sharply defined nuclear membrane. The nucleus generally is round, eccentrically located, and surrounded by a small amount of light blue staining cytoplasm. The volume of nucleus to cytoplasm in a lymphocyte typically is about 1:1.2. Lymphocytes can be differentiated from RBC in that RBC have no nuclei. Lymphocytes can be differentiated from neutrophils in that neutrophils have nuclei with 2 to 5 lobes, while lymphocyte nuclei are not lobed. Lymphocytes can be differentiated from basophils and eosinophils in that those cells have cytoplasmic granules, while lymphocytes do not have cytoplasmic granules. Lymphocytes can be differentiated from monocytes in that monocytes are 16 to 20 gm in diameter, while lymphocytes are 7 to 10 um in diameter. In addition, one of skill in the art may refer to any of a number of hematology or histological texts or atlases (e.g., Wheater et al. (1987) Functional Histology 2nd Ed. Churchill Livingstone, incorporated herein by reference in its entirety) to determine the physical appearance of a lymphocyte.
- ALC also can be determined by immunolabeling lymphocytes with antibodies specific for lymphocyte cell surface markers, and counting the immunolabeled cells using fluorescence flow cytometry (FFC). For example, NK cells can be labeled with one or more fluorescently labeled antibodies specific for CD16 and/or CD56. Similarly, B cells can be labeled with one or more fluorescently labeled antibodies specific for the adhesion molecules CD20 and/or CD19, and T cells can be labeled with one or more fluorescently labeled antibodies specific for CD3, CD4, and/or CD8, and. To determine ALC, cell surface marker-specific antibodies can be labeled with the same fluorophore (e.g., Cy-5, fluorescein, or Texas Red). In a FFC procedure, individual cells are held within a thin stream of fluid and passed through one or more laser beams, one cell at a time, causing light to scatter and the fluorescent dyes to emit light at various predetermined frequencies. Photomultiplier tubes convert the light to electrical signals, allowing for quantitation of the number of cells bearing the fluorophore. If all lymphocyte subtypes are labeled with the same fluorophore, quantification of the number of fluorophore-bearing cells will yield an ALC. FFC and quantitation is further described in, for example, U.S. Pat. No. 4,499,052. In addition, a FFC machine can be adapted for fluorescence activated cell sorting (FACS), i.e., the separation (and collection) of (a) fluorescent cells from non-fluorescent cells; (b) strongly fluorescent cells from weakly fluorescent cells; or (c) cells fluorescing at one wavelength from cells fluorescing at another wavelength.
- Monocytes are large phagocytic WBC that have a simple nucleus and clear, grayish cytoplasm. Monocytes can differentiate into macrophages and myeloid lineage dendritic cells. Classical monocytes are characterized by high level expression of the CD14 cell surface receptor without expression of the CD16 cell surface receptor, but other populations of monocytes are characterized by low level expression of CD14 and high level expression of CD16, or high level expression of CD14 and low level expression of CD16.
- The terns “absolute monocyte count” (AMC) refers to the total number of mature monocytes per unit of whole blood or blood cells in a sample or in a subject (e.g., a human patient). Again, a unit can be, for example, a L, mL, or μL. AMC can be determined by, for example, using an automated cell count machine or flow cytometry, as described above with regard to ALC.
- Once ALC and AMC have been determined, whether the A-ALC and A-AMC in a population of collected stem cells from a patient, or the ALC and AMC in a blood sample obtained from a subject, the ratio of lymphocytes to monocytes can be determined. The ratio of A-ALC to A-AMC for a population of autologous cells to be used in APBHSCT is referred to herein as A-LMR, while the ratio of ALC to AMC in a biological sample (e.g., a blood sample) collected from a subject is referred to herein as LMR. An A-LMR for a population of collected autologous stem cells that is at least 1.0 (e.g., 1.1, 1.2, 1.3, 1.4, 1.5, 2.0, 2.5, or greater than 2.5) can indicate that the patient receiving the APBHSCT has a greater likelihood of progression-free and overall survival than he/she would if the A-LMR was less than 1.0 (e.g., 0.9, 0.8, 0.7, 0.6, 0.5, or less than 0.5). Further, a LMR of at least 1.0 determined for a biological sample (e.g., a blood sample) obtained from a cancer patient at diagnosis, before or after chemotherapy, or from an APBHSCT recipient after transplant (e.g., 15, 30, 60, or 90 days post-transplant) can indicate that the patient has a greater likelihood of progression-free and overall survival than he/she would if the LMR was less than 1.0.
- This document also provides methods for assessing a patient's prognosis based on the ratio of NK cells to CD14+HLA-DRDIM monocytes in a biological (e.g., blood) sample from the patient, or in a population of collected autologous stem cells to be transferred back to the patient. NK cells can be collected using an apheresis procedure as described above. In some embodiments, the number of collected NK cells can be monitored. For example, the number of NK cells can be determined at one or more points during collection of the sample from the patient. The number of NK cells also can be determined after completion of a collection. Once the population of total collected cells includes at least about 0.5×109 NK cells/kg, they can be returned to the patient. The number of collected CD14+HLA-DRDIM cells also can be determined, and the ratio as compared to NK cells can be determined. The number of collected NK cells and CD14+HLA-DRDIM cells can be monitored using methods such as those described above. In some embodiments, the number of collected NK cells can be determined using immunolabeling with one or more fluorescently labeled antibodies specific for CD16 and/or CD56, and counting with FACS, while the number of collected CD14+HLA-DRDIM cells can be determined using immunolabeling with one or more labeled antibodies specific for CD14 and/or HLA-DRDIM, followed by counting with FACS.
- Once the numbers of NK cells and CD+HLA-DRDIM cells have been determined, whether the A-NK and A-CD14+HLA-DRDIM in a population of collected autologous cells to be used for APBHSCT, or the NKC and CD14+HLA-DRDIM in a blood sample obtained from a subject, the ratio of NK cells to CD14+HLA-DRDIM cells can be determined. A ratio of NK: CD14+FILA-DRDIM that is at least 0.29 (e.g., 0.30, 0.35, 0.40, 0.45, or more than 0.45) can indicate that the patient receiving the stern cells via APBHSCT has a greater likelihood of progression-free and overall survival than he/she would if the ratio was less than 0.29 (e.g., 0.28, 0.25, 0.23, 0.20, or less than 0.20). Further, a NK:CD14+HLA-DRDIM of at least 0.29 determined for a biological sample (e.g., a blood sample) obtained from a cancer patient at diagnosis, before or after chemotherapy, or from an APBHSCT recipient, post-transplant (e.g., 15, 30, 60, or 90 days post-transplant) can indicate that the patient has a greater likelihood of progression-free and overall survival than he/she would if the NK:CD14+HLA-DRDIM ratio was less than 0.29.
- The methods provided herein also can include treatment of a patient or a cell population (e.g., in a biological sample such as an apheresis product) with one or more agents that stimulate proliferation, maturation, differentiation, function, and/or activity of immune cells (e.g., lymphocytes, including NK cells). For example, a patient or a population of collected cells can be contacted with an agent such as IL-2, IL-12, IL-15, IL-17, IL-21, interferon alpha (IFN-α), or interferon gamma (IFN-γ). These agents can be native factors obtained from a natural source, factors produced by recombinant DNA methodology, chemically synthesized polypeptides or molecules, or any derivative having the functional activity of the native factor. Since agents such as these can enhance the number and/or activity of lymphocytes (e.g., NK cells), a patient may be subjected to shorter or fewer apheresis procedures in order to harvest a cell population containing, for example, an A-LMR or LMR of at least 1.0, and/or an A-NK;A-CD14+HLA-DRDIM of at least 0.29.
- In some embodiments, a population of collected cells can be contacted with an agent or platform that depletes monocytes. In some cases, the population of cells may be identified as having an A-LMR or LMR less than 1.0, or an A-NK;A-CD14+HLA-DRDIM or NK:CD14±HLA-DRDIM less than 0.29. Suitable methods for depleting monocytes include, for example, contacting a population of cells with a support (e.g., a solid surface such as a bead) coupled to CD14 (e.g., CD14 microbeads; Mitenyi Biotec), and collecting the cells that do not bind to the support.
- In some embodiments, a population of cells (e.g., a population of collected autologous lymphocytes containing NK cells and monocytes) can be contacted in vitro with one or more agents such as those listed above. For example, collected cells can be placed in a vessel (e.g., a bag, a tube, a vial, or any other suitable container) and contacted with one or more agents such as those described above. In some embodiments, cells can be contacted in vitro with IL-2 at a dose of, for example, about 1.5×106 to about 2.0×106 units. Lymphocyte (e.g., NK cell) enhancing agents can be added to cells within a container such as a bag (e.g., a blood bag), tube, or vial, or such a vessel can contain one or more such agents prior to placement of cells within the vessel. In some embodiments, one or more agents can be dispersed on an inner surface of the vessel. For example, an agent in liquid form can be dispersed (e.g., sprayed) onto an inner surface of the vessel and allowed to dry.
- Alternatively, an agent in solid (e.g., lyophilized or powdered) form can be dispersed on an inner surface of the vessel. In another alternative, an agent in liquid or solid form can simply be placed within the vessel.
- Alternatively, one or more lymphocyte enhancing agents can be administered to a patient. A patient can be treated with such an agent prior to collection of a biological sample containing lymphocytes and monocytes, or a patient can be treated post-APBHSCT. For example, the number of NK cells in the PB of a patient can be monitored following APBHSCT, and a NK cell enhancing agent can be administered to the patient if the number of NK cells is below a particular threshold at a particular time point (e.g., at post-transplant day 15). A suitable threshold can be, for example, about 80 NK cells/μL of blood (e.g., about 75 NK cells/μL or about 85 NK cells/μL). Similarly, a NK cell enhancing agent can be administered to a patient post-APBHSCT if the ALC-15 is less than 500 cells/μL of blood. Agents such as those listed above can be administered to a patient via any pharmaceutically acceptable route known in the art, including, for example, intravenous injection, intra-arterial injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, or oral administration in the form of a tablet, capsule, or syrup. In some embodiments, IL-2 can be administered to a patient prior to collection of autologous cells, or after APBHSCT. In another embodiment, a patient can be treated with IFN-γ at a concentration of, for example, between about 1×105 and about 1×107 units/m2. When the treatment is post-APBHSCT, the agent(s) can be administered from the day of transplant up to about 21 days following the transplant.
- In some embodiments, patients or collected cell populations (e.g., populations containing lymphocytes and monocytes) also can be treated with one or more agents that activate the T cell signal transduction pathway, leading to lymphocyte activation. A T cell activator can be, without limitation, one or more of the following: IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, IL-13, IFNα, IFNγ, tumor necrosis factor (TNFα), an anti-CD3 antibody or antigen-binding fragments thereof (anti-CD3), an anti-CD28 antibody or antigen-binding fragments thereof (anti-CD28), phytohemagglutinin, concanavalin-A, and phorbol esters. As above, these agents can be native factors obtained from a natural source, factors produced by recombinant DNA methodology, chemically synthesized polypeptides or molecules, or any derivative having the functional activity of the native factor.
- The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
- Retrospective studies were conducted to determine whether the A-LMR for autologous cells infused into DLBCL patients during APBHSCT could be correlated to survival. In a training. set including 253 patients, and also in a validation set containing 126 patients, an A-LMR of 1 or higher correlated with increased overall survival (
FIGS. 1A and 1B, top panels), increased progression-free survival (FIGS. 1A and 1B , middle graphs), and increased lymphoma-specific survival (FIGS. 1A and 1B , bottom graphs), while an A-LMR less than 1 correlated with decreased overall survival (FIGS. 1A and 1B , top panels), decreased progression-free survival (FIGS. 1A and 1B , middle graphs), and decreased lymphoma-specific survival (FIGS. 1A and 1B , bottom graphs). Details of these studies are provided elsewhere (Porrata et al. (2014) Biol Blood Marrow Transplant 20:1804-1812). - A double-blind, phase III, randomized clinical trial was conducted to determine whether A-NK:A-CD14+HLA-DRDIM can be used as a predictor of survival in 111 non-Hodgkin's lymphoma (NHL) patients. The primary end point of was to assess the impact of A-NKC/ACD14+HLA-DRDIM ratio on overall survival (OS) and progression-free survival (PFS). A secondary end point was to determine whether the A-NKC/A-CD14+HLA-DRDIM ratio is an independent prognostic factor for OS and PFS.
- The prognostic factors evaluated in this study included: international prognostic index (IPI “The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma.,” N Engl J Med 1993, 329:987-994) at diagnosis (≤2), age at
diagnosis 60 vs. >60 years), lactate dehydrogenase (LDH) at diagnosis (>normal), ECOG (Eastern Cooperative Oncology Group) performance status at diagnosis (>1 vs. ≤1), extranodal sites at diagnosis (>1 versus ≤1), stage at diagnosis (III/IV vs. I/II), histologies at diagnosis (DLBCL vs. others), disease status before APBHSCT (complete response vs. partial response), infused CD34′ cell count, Plerixafor use, and A-NKC/A-CD14+HLA-DRDIM ratio. Basic characteristics of the study participants are shown in TABLE 1. Further details of these studies are described elsewhere (Porrata et al. 2016, supra; and Kansagra et al. 2018, Bone Marrow Transplantation 53:146-154). - The double-blind, randomized, phase III clinical trial was designed to assess whether the PFS was significantly increased among those patients whose apheresis was done using a modification to a standard Fenwal Amicus setting where the mononuclear cell offset=1.5 and RBC=6.0, compared with settings where mononuclear cells =1.5 and RBC=5.0.
- For stem cell mobilization, patients received 10lig/kg of G-CSF subcutaneously (SC) daily for 5 to 7 consecutive days alone or in conjunction with 0.24 mg/kg of Plerixafor for up to 4 consecutive days by SC injection. Patients started with G-CSF and after 4 days of treatment, if the peripheral blood CD341- count was >10 cellsluL, stem cell collection began. If the peripheral blood CD34′ count was <10 cells/RL, Plerixafor was added that evening and collections were initiated the next day. Apheresis collections were to be performed daily, with a goal of at least 2×106CD34+cells/kg. Additional collections were at the discretion of the transplantation team. Patients who failed mobilization or did not collect at least 2×106 CD34. ′ cells/kg were allowed to choose to either undergo a second mobilization/apheresis or discontinue study participation.
- For conditioning, all patients received BEAM chemotherapy: BCNU (carmustine, 300 mg/m2) on day −6, Etoposide (100 mg/m2) twice daily from days −5 to −2, ARA-C (Cytarabine, 100 mg/m2) twice daily from days −5 to −2, and Melphalan (140 mg/m2) on day −1.
- OS was measured from the date of APBHSCT to the date of death or last follow-up, and PFS was defined as the time from APBHSCT to time of progression, relapse, death or last follow-up (Cheson et al. 2007, J Gin Oncol 25:579-586).
- Previously frozen autograft mononuclear cells (0.5-1.0×106 cells/mL) were thawed and aliquoted into 96-well round-bottomed plates (100 mL/well). The following monoclonal antibodies were used for autograft mononuclear cell immunophenotyping by flow cytometry: anti-human CD3 FITC, anti-human CD16 phycoerythrin (PE), and anti-human CD56 PE for NK cells, and anti-human CD14 FITC and anti-human HLA-DR PE-cyanin 5.5 (PE-Cy5.5) for HLA-DR dim monocytes (BD Pharmingen; San Jose, Calif.). The desired antibody or antibody pool was added at 5 uL of each antibody/well. The cells and antibodies were incubated for 30 minutes at 4° C. and washed twice with 1 x PBS (Cellgro; Manassas, Va.), 0.1% BSA and 0.05% sodium azide (Sigma; St Louis, Mo.). Three-color flow cytometry was performed on a Guava 8-HT (Millipore; St Louis, Mo.) and Incyte software (Millipore) was utilized for data analysis. After gating on live lymphocytes, the percentage of NK cells was determined by the number of cells that were CD3 negative and CD16 and CD56 positive. For the HLA-DeDIM cells, gates were set on live cells, and CD14-positive cells and HLA-DRDIM cells were enumerated from the CD14-positive gate. The absolute numbers of autograft NK cells and autograft CD14+HLA-DRDIM cells were calculated by multiplying their percentage times the A-ALC for NK cells and autograft absolute monocyte count (A-AMC) for CD14+FILA-DRDIM cells for each apheresis unit collection. The A-ALC was calculated as follows: A-ALC=% collection lymphocytes x (absolute WBC/kg). In a similar manner, the A-AMC was calculated as follows: A-AMC=% collection monocytes x (absolute WBC/kg).
- OS and PFS were analyzed using the approach of Kaplan-Meier (Kaplan and Meier 1958, J A117 Stat Assoc 53:457-481). Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. Univariate and multivariate analysis was performed using Cox proportional hazard model (Cox 1972, J R Stat Soc 34:187-202). The variables in the prognostic factor section were evaluated to assess their impact on OS and PFS times post APBHSCT. The choice of the cutoff value for the A-NKC/A-CD14+HLADR DIM ratio to assess survival was based on its utility as a marker for the clinically relevant binary outcome of death/survival using the receiver operating characteristics curves (ROC) and area under the curve (AUC). The binary clinical outcome (death/survival) was established at 5 years after APHSCT. Patients were classified as ‘alive/censored’ when follow-up time was >5 years and ‘death/uncensored’ for patients known to have died before this time point (Tzankov et al. 2010, Leak Lymphoma 51:199-212). A K-fold cross-validation with K-values of 10 was performed to validate the results of A-NKC/ACDl44HLADRDTM ratio cutoff obtained by the ROC and AUC curves.
- Randomly chosen subsets containing 90% of the cohort were used for training, and the remaining 10% were left for testing. The cross-validation process was then repeated 10 times. Based on this analysis, cross-validation AUC by the ROC was produced, representing the discriminating accuracy of A-NKC/A-CD14+HLA-DRDIM ratio for the binary clinical outcomes of death/survival.
- The X2 tests and Fisher's exact tests were used to determine relationships between categorical variables as appropriate. The Wilcoxon rank test was used to determine associations between continuous variables and categories and nonparametric tests were used to evaluate associations for continuous variables. All P-values represented were two sided and statistical significance was declared at P<0.05.
- The median age at the time of APBHSCT was 57 years (range: 20-74). The distribution of additional baseline characteristics for this cohort is presented in TABLE 1. The median follow-up from APHSCT was 57.2 months (range: 2.1-84.6 months) and 62.6 months (range: 37.6-84.6 months) for patients who were alive (n=72). The day-100 transplantation-related mortality was 1.8% (2/111): one patient died because of septic shock and one patient died of acute respiratory distress syndrome. Other than the two patients who died in the first 100 days after APBHSCT, 35 patients died because of relapse/progression of lymphoma and two patients died of myocardial infarction.
- Representative fluorescence-activated cell sorting (FACS) plots to calculate the percentage of A-NKC are shown in
FIGS. 2A and 2B , and representative FACS plots to calculate the percentage of A-CD14+FILA-DRD11″FIGS. 2C-2E . ROC curves and AUC were used to determine the optimal cutoff points for A-NKC, A-CD14−′HLA-DRDIM and A-NK:A-CD14−41 LA-DRDim ratio based on their utility as markers for the clinical binary outcome of death/survival. The A-NKC >0.09×109 cells/kg had an AUC of 0.65 (95% CI, 0.59-0.71), with a sensitivity of 50% (95% CI, 45-55%) and a specificity of 81% (95% CI, 77-85%), P<0.04. The A-CD14−1-1Ek-DRDIM >0.21×109 cells/kg had an AUC of 0.74 (95% CI, 0.68-0.80), with a sensitivity of 49% (95% CI, 43-55%) and a specificity of 92% (95% CI, 85-99%), P<0.001. The A-NK:A-CD l′FHLA-DRDIM ratio >0.29 had an AUC of 0.75 (95% CI, 0.70-0.80), with a sensitivity of 60% (95% CI, 55-65%) and a specificity of 89% (95% CI, 84-94%), P<0.0003 (FIG. 3A ). - An internal validation of A-NKC,
A-CD14 −11 LA-DRDim and A-NK:A-CD14−}ILA DRDIM ratio performances as markers for the clinical binary outcomes of death/survival was performed using k-fold cross-validation with k=10. For A-NKC, the cross-validation ROC showed an AUC of 0.66 (95% CI, 0.66-0.72); for A-CD1411LA-DRDIM, an AUC of 0.76 (95% CI, 0.71-0.81); and for A-NK:ACD141-1LA-DRDIM . ratio, an AUC of 0.76 (96% CI, 0.70-0.82) (FIG. 3B ). The similar AUC from the empirical ROC and the cross-validation ROC curves support the use of A-NKC >0.09×109 cells/kg, A-CD141-ILA-DRDIM ≥0.21×109 cells/kg, and the A-NK:A-CD14 +HLADRDIM ratio of>0.29 for cutoff values as markers of the binary clinical outcome of death/survival. - Based on the univariate Cox regression analysis, A-NK:A-CD14−′HLA-DRDIM ratio >0.29 was a predictor for OS and PFS (see, TABLES 2A and 2B). A strong positive correlation was identified between A-NKC and A-NK:A-CD1411LA-DRDim ratio >0.29 (r=0.63, P<0.0001), and a strong negative correlation between A-CD14−41 LA-DRDIM and A-NK:A-CD1411LA-DRDIM ratio <0.29 (r=−0.70, P<0.0001). To avoid the problem of collinearity due to the strong correlation between A-NKC and A-NK:A-CD1411LA-DRDim ratio, and between A-CD14+11 LA-DRDIM and A-NK:A-CD141-1LA-DRDIM ratio, two separated multivariate analyses were performed. The first multivariate analysis included A-NKC and A-CD14−′HLA-DRDTM with the other prognostic factors in TABLES 2A and 2B, excluding the A-NK:A-CD1411LA-DRDIM ratio. In this first multivariate analysis, both were independent predictors for OS (A-NK: hazard ratio (HR)=0.34, 95% CI, 0.15-0.76, P <0.006; and A-CD14−′HLA-Delm: HR=2.53, 95% CI, 1.12-6.05, P<0.03) and for PFS (A-NK: HR=0.31, 95% CI, 0.16-0.58, P<0.0001; and A-CD141-HLA-DRD1m: HR=2.05, 95% CI, 1.14-3.76, P<0.03). In the second multivariate analysis, A-NKC and A-CD1441LA-DRDIM were excluded, and the A-NK:A-CD14′HLA-DRDIM ratio was included in the analysis. TABLE 3 shows that the A-NK:A-CD14+11 LA-Delm ratio was an independent prognostic factor for OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002) and for PFS (HR=0.56, 95% CI, 0.32-0.96, P<0.03).
- Patients were categorized into two groups (A-NK:A-CD14HLA-DR′TM ratio >0.29 vs. A-NK:A-CD14−41 LA-DRDIM ratio <0.29) to assess whether both groups were balanced with regard to the baseline patient characteristics. As shown in TABLE 4, both groups were balanced, except for LDH, the disease status before APBHSCT, and the use of Plerixafor.
- To evaluate survival outcomes based on A-CD14+HLA-DRDIM and A-NK:A-CD14−′+HLA-DRDIM ratio, A-CD14±FILA-DRDIM >0.21×109 cells/kg and A-NK:A-CD1441LA-Delm ratio >0.29 were tested for OS and PFS. Patients infused with an A-CD14A-ILA-DRDIm<0.21×109 cells/kg vs. patients infused with an A-CD144-HLA-DRDIm 0.21×109 cells/kg experienced superior OS (
FIG. 4A ) and PFS (FIG. 4B ): median OS of not reached vs. 73.1 months, 5-year OS rates of 83% (95% CI, 70-95%) vs. 52% (95% CI, 39-56%), P<0.0005, respectively, and median PFS of not reached versus 31.1 months, 5-year PFS rates of 60% (95% CI, 47-72%) vs. 34% (95% CI, 22-47%), P<0.004, respectively. Further, patients infused with an A-NK:A-CD14fHLA-DRDIM ratio >0.29 vs. patients infused with an A-NK:A-CD14. 41 LA-DRI′m ratio <0.29 experienced superior OS (FIG. 4C ) and PFS (FIG. 4D ): median OS of not reached vs. 56.2 months, 5-year OS rates of 84% (95% CI, 72-91%) vs. 48% (95% CI, 34-62%), P<0.0002, respectively; and median PFS of not reached vs. 31.1 months, 5-year PFS rates of 59% (95% CI, 46-71%) vs. 34% (95% CI, 22-47%), P<0.002, respectively. - Patients with an IPI index of 0-2 experienced better OS and PFS with an A-NK:A-CD14. 41 LA-DRDIM ratio >0.29 compared with an A-NK:A-CD14−1HLA-DRDIM ratio <0.29, but patients with an IPI index of 3-4 did not (
FIGS. 4A and 4B ). For the subset of patients with DLBCL, those who received an A-NK:A-CD14+HLA-DRDIM ratio >0.29 experienced better OS and PFS than with patients with an A-NK:A-CD14−1-HLA-DRDIM ratio <0.29 (FIGS. 4C and 4D ). In the DLBCL group, the A-NK:A-CD1411LA-De1m ratio >0.29 was an independent predictor for OS (HR=0.26, 95% CI, 0.16-0.43, P<0.0002) and PFS (HR=0.28, 95% CI, 0.18-0.55, P<0.0003). -
TABLE 1 Baseline patient characteristics Variables N (%) Age, year, median (range) 55 (20-73) Age, years ≤60 71 (64%) >60 40 (36%) Gender Male 80 (72%) Female 31 (28%) Histology DLBCL 51 (46%) Follicular lymphoma 16 (14%) Mantle cell lymphoma 25 (23%) Other 19 (17%) LDH (U/L), median (range) 211 (106-3364) LDH Normal 58 (52%) Abnormal 53 (48%) Stage I 7 (6%) II 11 (10%) III 27 (24%) IV 66 (60%) Stage I/II 18 (16%) II1/IV 93 (84%) Extra-nodal disease 0 51 (46%) 1 52 (47%) 2 8 (7%) Extra-nodal disease ≤1 103 (93%) >1 8 (7%) Performance status 0 28 (25%) 1 71 (64%) 2 12 (11%) Performance status ≤1 99 (89%) >1 12 (11%) IPI score 0 15 (13%) 1 34 (31%) 2 32 (29%) 3 25 (23%) 4 5 (4%) IPI Index ≤2 81 (73%) >2 30 (27%) At PBSC collection Age, years: median (range) 57 (20-74) Clinical status pre-transplant Complete response 63 (57%) Partial response 48 (43%) Number of chemotherapy regimens 1 35 (32%) 2 65 (58%) 3 7 (6%) 4 3 (3%) 5 1 (1%) Apheresis machine ModC 56 (50%) StdC 55 (50%) Number of apheresis collections 1 8 (7%) 2 22 (19%) 3 24 (22%) 4 25 (23%) 5 17 (15%) 6 5 (5%) 7 8 (7%) 8 2 (2%) Plerixafor Yes 44 (40%) No 67 (60%) Infused CD34+ cells × 106/kg: median (range) 5.15 (2.02-11.37) -
TABLE 2A Overall survival Progression-free survival Dichotomized Variables HR 95% CI P HR 95% CI P Age > 60 years 1.55 0.81-2.93 0.2 1.18 0.69-1.97 0.5 Elevated LDH 2.40 1.26-4.74 <0.007 1.56 0.94-2.62 0.09 Stage III/IV 1.50 0.69-4.38 0.4 2.72 1.20-7.82 <0.01 Extra-nodal involvement > 1 5.312 2.12-11.60 <0.001 3.35 1.38-6.97 <0.01 Performance status 1.48 0.51-3.50 0.4 1.29 0.53-2.65 0.5 IPI ≥ 2 2.27 1.18-4.28 <0.02 1.81 1.04-3.05 <0.04 Complete vs partial response 0.51 0.26-0.96 <0.03 0.41 0.24-0.68 <0.0001 prior to transplant DLBCL vs other 0.54 0.28-0.99 <0.05 0.95 0.57-1.59 0.9 Female vs male 2.03 1.04-0.55 <0.05 1.47 0.83-0.74 0.3 A-NKC ≥ 0.09 × 109 cells/kg 0.34 0.14-0.70 <0.003 0.09 0.14-0.52 <0.0001 A-CD14 + HLA-DRDIM ≥ 0.21 × 3.26 1.66-6.89 <0.0005 2.14 1.27-3.69 <0.004 109 cells/kg A-NK:A-CD14+HLA-DRDIM 0.28 0.14-0.55 <0.0002 0.44 0.26-0.74 <0.002 ratio ≥ 0.29 Infused CD34 0.39 0.05-2.51 0.3 0.42 0.08-1.86 0.3 Plerixafor 1.32 0.69-2.53 0.4 1.35 0.80-2.27 0.3 -
TABLE 2B Overall survival Progression-free survival Continuous Variables HR 95% CI P HR 95% CI P A-NKC 0.26 0.06-0.96 <0.04 0.18 0.05-0.56 <0.002 A-CD14+HLA-DRDIM 5.83 1.86-15.97 <0.004 2.92 1.07-7.07 <0.04 A-NKC/A-CD14+HLA-DRDIM ratio 0.07 0.01-0.30 <0.0001 0.15 0.05-0.37 <0.0001 Infused CD34+ cells 0.39 0.05-2.51 0.3 0.42 0.08-1.86 0.3 -
TABLE 3 Overall survival Progression-free survival Variables HR 95% CI P HR 95% CI P Female vs male 1.84 0.92-3.56 0.08 Complete vs partial response 0.55 0.27-1.05 0.09 0.65 0.37-1.14 0.1 prior to transplant DLBCL vs other 0.53 0.27-1.01 0.06 IPI ≥ 2 1.01 0.39-2.60 0.9 1.35 0.70-2.48 0.4 A-NK:A-CD14 + HLA-DRDIM 0.34 0.16-0.68 <0.002 0.56 0.32-0.96 <0.03 ratio ≥ 0.29 Extra-nodal disease > 1 3.23 1.06-9.47 <0.04 2.07 0.77-5.13 0.1 Elevated LDH 1.54 0.63-3.59 0.3 Stage III/IV 1.87 0.78-5.55 0.2 -
TABLE 4 Baseline characteristics based on A-NK:A-CD14+ HLA-DRDIM ratio A-NK:A-CD14 + A-NK:A-CD14 + HLA-DRDIM HLA-DRDIM Variables ≥0.29 (n = 57) <0.29 (n = 54) P Age, year, 58 (20-74) 56.5 (24-74) 0.6 median (range) Male 41 (72%) 39 (72%) 0.9 Female 16 (28%) 15 (28%) LDH (g/dL), 190 (120-913) 232 (106-365) <0.04 median (range) Extra-nodal 0.2 disease 0 29 (51%) 22 (41%) 1 26 (45%) 26 (48%) 2 2 (4%) 6 (11%) Performance 0.7 status 0 16 (28%) 12 (22%) 1 26 (63%) 35 (65%) 2 5 (9%) 7 (13%) Histologies 0.9 DLBCL 25 (44%) 26 (48%) Follicular 8 (14%) 8 (15%) Mantle cell 13 (23%) 12 (22%) Other 11 (19%) 8 (15%) Stage 0.3 I 5 (9%) 2 (4%) II 8 (14%) 3 (6%) III 12 (21%) 15 (28%) IV 32 (56%) 34 (62%) IPI score 0.06 0 13 (22%) 2 (4%) 1 16 (28%) 18 (33%) 2 14 (25%) 18 (33%) 3 12 (21%) 13 (24%) 4 2 (4%) 3 (6%) IPI risk factors Age, years 0.8 >60 20 (35%) 20 (37%) ≤60 37 (65%) 34 (63%) Extra-nodal 0.2 disease ≥2 2 (4%) 6 (11%) <2 55 (96%) 48 (89%) LDH 0.3 Abnormal 24 (42%) 29 (54%) Normal 33 (58%) 25 (46%) Performance 0.6 status 1 5 (9%) 7 (13%) ≤1 52 (91%) 47 (87%) Stage 0.07 I/l 13 (23%) 5 (9%) III/IV 44 (77%) 49 (91%) IPI Index 0.7 2 14 (25%) 16 (30%) ≤2 43 (75%) 38 (70%) Clinical status <0.003 pre-transplant Complete 40 (70%) 23 (43%) response Partial 17 (30%) 31 (57%) response Plerixafor <0.004 Yes 15 (26%) 29 (54%) No 42 (74%) 25 (46%) Infused CD34 5.15 (2.0-11.37) 5.14 (2.27-8.15) 0.4 cells/kg, median (range) Apheresis 0.3 machine ModC 26 (46%) 30 (56%) StdC 31 (54%) 24 (44%) Number of 0.5 apheresis collections 1 5 (9%) 3 (6%) 2 9 (16%) 13 (24%) 3 14 (25%) 10 (18%) 4 11 (19%) 14 (26%) 5 11 (19%) 6 (11%) 6 3 (5%) 2 (4%) 7 4 (7%) 4 (7%) 8 0 (0%) 2 (4%) ModC = modified apheresis machine StdC = standard apheresis machine - It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (13)
1. A method for treating a cancer patient, said method comprising:
(a) identifying the patient as having a biological sample with a lymphocyte:monocyte ratio (LMR) less than 1.0; and
(b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent.
2. The method of claim 1 , wherein the immunotherapeutic agent is interleukin-15 (IL-15), interleukin-21 (IL-21), or a combination of IL-15 and IL-21.
3. The method of claim 1 , wherein the LMR was determined at initial diagnosis of the cancer or prior to treatment.
4. The method of claim 1 , wherein the patient has received an autologous peripheral hematopoietic stem cell transplantation (APBHSCT), and wherein the LMR was calculated using absolute lymphocyte count and absolute monocyte count in a blood sample obtained from the patient after the APBHSCT.
5. The method of claim 1 , wherein the patient was treated with chemotherapy, and wherein the LMR was calculated using absolute lymphocyte count and absolute monocyte count within a blood sample obtained from the patient after the chemotherapy.
6. The method of claim 1 , wherein the cancer is selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, non-Hodgkin's lymphoma, breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
7. The method of claim 1 , comprising identifying the patient as having a LMR less than 0.8, and administering a pharmaceutical composition comprising IL-15, IL-21, or a combination of IL-15 and IL-21.
8. A method for treating a cancer patient, said method comprising:
(a) identifying the patient as having a biological sample as containing an A-CD14HLA-DRDIM cell count that is greater than or equal to 0.21×109 cells/kg; and
(b) administering to the patient a pharmaceutical composition comprising an immunotherapeutic agent.
9. The method of claim 8 , wherein the immunotherapeutic agent is IL-15, IL-21, or a combination of IL-15 and IL-21.
10. The method of claim 8 , wherein the number of A-CD1411LA-DRDim cells was determined at initial diagnosis of the cancer or prior to treatment.
11. The method of claim 8 , wherein the patient has received an APBHSCT, and wherein the A-CD14+HLA-DRDIM count was calculated using absolute CD14+HLA-DRDIM count in a blood sample obtained from the patient after the APBHSCT.
12. The method of claim 8 , wherein the patient was treated with chemotherapy, and wherein the LM A-CD14+HLA-DR DIM count was calculated using absolute A-CD14+HLA-DR DIM count within a blood sample obtained from the patient after the chemotherapy.
13. The method of claim 8 , wherein the cancer is selected from the group consisting of diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, classical Hodgkin's lymphoma, non-Hodgkin's lymphoma, breast cancer, lung cancer, ovarian cancer, liver cancer, kidney cancer, esophageal cancer, gastric cancer, and pancreatic cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/876,791 US20230039835A1 (en) | 2017-02-21 | 2022-07-29 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762461663P | 2017-02-21 | 2017-02-21 | |
PCT/US2018/018744 WO2018156493A1 (en) | 2017-02-21 | 2018-02-20 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
US201916486863A | 2019-08-19 | 2019-08-19 | |
US17/876,791 US20230039835A1 (en) | 2017-02-21 | 2022-07-29 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/018744 Division WO2018156493A1 (en) | 2017-02-21 | 2018-02-20 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
US16/486,863 Division US11439684B2 (en) | 2017-02-21 | 2018-02-20 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230039835A1 true US20230039835A1 (en) | 2023-02-09 |
Family
ID=63254025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/486,863 Active US11439684B2 (en) | 2017-02-21 | 2018-02-20 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
US17/876,791 Pending US20230039835A1 (en) | 2017-02-21 | 2022-07-29 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/486,863 Active US11439684B2 (en) | 2017-02-21 | 2018-02-20 | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof |
Country Status (2)
Country | Link |
---|---|
US (2) | US11439684B2 (en) |
WO (1) | WO2018156493A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023081386A1 (en) * | 2021-11-04 | 2023-05-11 | The Regents Of The University Of Michigan | Prevention and treatment of cytokine release syndrome and neurotoxicity associated with car-t cell therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499052A (en) | 1982-08-30 | 1985-02-12 | Becton, Dickinson And Company | Apparatus for distinguishing multiple subpopulations of cells |
KR970007077B1 (en) | 1987-03-13 | 1997-05-02 | 코울터 일렉트로닉스 인커퍼레이티드 | Multi-part diefferential analyzing apparatus using light scatter techniques |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US20040009150A1 (en) * | 2002-06-07 | 2004-01-15 | Nelson Andrew J. | Methods of treating cancer using IL-21 |
WO2006004592A2 (en) | 2004-05-28 | 2006-01-12 | Mayo Foundation For Medical Education And Research | Methods for autologous stem cell transplantation |
WO2011031676A2 (en) * | 2009-09-10 | 2011-03-17 | Mayo Foundation For Medical Education And Research | Depleting immunosuppressive monocytes within a mammal |
WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
WO2017053671A1 (en) | 2015-09-24 | 2017-03-30 | Mayo Foundation For Medical Education And Research | Methods for autologous stem cell transplantation |
US20180286508A1 (en) * | 2015-10-09 | 2018-10-04 | Mayo Foundation For Medical Education And Research | Determination of favorable date(s) for therapeutic treatment delivery |
-
2018
- 2018-02-20 US US16/486,863 patent/US11439684B2/en active Active
- 2018-02-20 WO PCT/US2018/018744 patent/WO2018156493A1/en active Application Filing
-
2022
- 2022-07-29 US US17/876,791 patent/US20230039835A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11439684B2 (en) | 2022-09-13 |
US20200230209A1 (en) | 2020-07-23 |
WO2018156493A1 (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gutman et al. | Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit | |
Maury et al. | CD4+ CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation | |
Bomberger et al. | Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors | |
US20140369955A1 (en) | Methods for autologous stem cell transplantation | |
US20200124603A1 (en) | Methods and kits for identifying effector treg cells | |
Zeng et al. | Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia | |
US20230039835A1 (en) | Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof | |
CN106434552B (en) | Novel NKT-like cell subsets and their use for treating tumors | |
JP2021165292A (en) | Hematologic malignancy therapeutic agent, and screening method | |
Meehan et al. | Adoptive cellular therapy using cells enriched for NKG2D+ CD3+ CD8+ T cells after autologous transplantation for myeloma | |
Desai et al. | Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans | |
Bojanic et al. | Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers | |
US20180264084A1 (en) | Methods for autologous stem cell transplantation | |
WO2002038189A1 (en) | Absolute lymphocyte recovery and cancer survival | |
JP4443935B2 (en) | Cell competence testing to predict hematopoietic recovery, neutropenic fever, and antibacterial treatment after high-dose cytotoxic chemotherapy | |
US20120107293A1 (en) | Methods and compositions for the treatment of cancer | |
Kenswil et al. | Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia | |
Nagatoshi et al. | Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population | |
Freudenreich et al. | In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS | |
Lamb | Hematopoietic cellular therapy: implications for the flow cytometry laboratory | |
Sieńko et al. | Correlation between stem and progenitor cells number and immune response in patients after allogeneic kidney transplant | |
Flint et al. | Targeting the expansion of myeloid-derived suppressor cells in liver cirrhosis | |
HASBAL et al. | Stem Cell Mobilization Efficiency and Engraftment Kinetics in Patients with Hematologic Malignancies Undergoing Autologous Stem Cell Transplantation: A Retrospective Cohort Study | |
Joao et al. | Immunologic autograft engineering by manipulation of apheresis machine collection settings | |
Valtola | Graft and Outcome in Autologous Stem Cell Transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PORRATA, LUIS F.;MARKOVIC, SVETOMIR N.;SIGNING DATES FROM 20180712 TO 20180820;REEL/FRAME:061562/0991 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |